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ABSTRACT
PREFORMULATION STUDIES FOR THE PREPARATION OF AMORPHOUS
SOLID DISPERSIONS

Hemanth K. Mamidi

The major challenges in the formulation of amorphous solid dispersions (ASDs)
using hot-melt extrusion (HME) are the selection of an ideal polymeric carrier,
optimization of HME processing conditions, and screening of the physical stability of the
ASDs. Addressing these challenges using traditional approaches require extensive
experimentation and large amounts of active pharmaceutical ingredients (API) which
may not be feasible during the initial stages of product development. Therefore, there is a
need to develop material-sparing techniques for the successful formulation of ASDs. The
objective of the present study was to develop material-sparing techniques that can be
used as pre-formulation tool during the formulation of ASDs. For this purpose,
mefenamic acid (MFA) was used as a model drug and four chemically distinct polymers
with close values of the solubility parameters, viz. Kollidon® VA64, Soluplus®, Pluronic®
F68, and Eudragit® EPO, were used as polymeric carriers. The selection of an ideal
polymer was carried out based on the solubility parameter approach, melting point
depression method, thermodynamic phase diagrams, and Gibbs free energy plots. Then
the HME processing conditions were determined based on a material-sparing technique
using differential scanning calorimeter (DSC). The physical stability of the ASDs was
estimated using the modified Avarami equation. Based on the results of the melting point
depression, thermodynamic phase diagrams and Gibbs free energy plots, Eudragit® EPO

was found to be an ideal polymer for the preparation of amorphous solid dispersion
formulation of mefenamic acid. The design space for HME determined using DSC
method showed that when 20% drug loaded MFA-EPO blends was heated at a rate of 5.5
°C/min to a temperature of 146 °C, the resulting ASD contained a residual crystallinity of
13.6% and drug degradation of 3.8%. The physical stability of the MFA-EPO ASDs
determined using a modified Avarami equation showed that the rate of recrystallization
changed significantly with the change in process temperature as compared to the change
in the relative humidity. The study results show that the time frame and experiments
required in the formulation of ASDs can be significantly reduced by using the materialsparing techniques developed based on the theoretical and experimental approaches.
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1. Introduction
Poor aqueous solubility of drugs is one of the major challenges in the
pharmaceutical industry. Enhancing the oral bioavailability of poorly aqueous soluble
drugs by improving their solubility remains one of most challenging aspects of drug
development process. Various traditional and newer approaches have been developed to
improve the solubility of poory water soluble drugs. The traditional methods include
solid dispersion, complexation and pH adjustment while newer methods include
liquisolid technology, hydrotropy, lipid-based system, etc. The choice of technique is
selected based on the properties of drug, nature of excipients and the intended dosage
form. Out of all the techniques to improve solubility, solid dispersion formulation
remains one of the widely used technique due to its simplicity and ease of
commercialization.

1.1. Solid Dispersions
Sekiguchi and Obi in 1961 first proposed the concept of solid dispersions (1).
They described solid dispersions as the biphasic systems of drug particles dispersed in a
polymeric carrier. Over the decades, various other definitions of solid dispersions were
proposed. Most recently, Janssens et al. defined solid dispersions as, “Formulations of
poorly-soluble compounds which might lead to particle size reduction, improved wetting,
reduced agglomeration, changes in the physical state of the drug and possibly dispersion
on a molecular level, according to the physical state of the solid dispersions that depends
on the physicochemical properties of carrier and the drug, the drug-carrier interaction and
the method of preparation” (2). Solid dispersions are divided into various types on the
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basis of the crystalline nature of the drug molecules and their distribution in the carrier
matrix as shown in Table 1. Type I solid dispersions are eutectic mixtures in a specific
ratio and have a single melting point which is lower than the melting point of the
individual components. Type II solid dispersions are amorphous precipitates in
crystalline matrix where the drug is present in amorphous form dispersed in crystalline
polymeric matrix. Type III solid solutions are similar to Type II but the drug is
molecularly dispersed in the polymeric carrier. It can be either monophasic or biphasic.
In type IV, V and VI solid dispersions, the drug is either in crystalline, amorphous or
molecularly dispersed form, respectively in an amorphous polymeric matrix. To obtain a
glassy solution, the drug should be completely miscible in the polymeric matrix. Type
IV, V and VI solid dispersions are prominent now a days and are prepared using spraydrying or hot-melt extrusion technique. Type IV is achieved if the drug is dispersed as
crystals in the amorphous polymer phase. This is a two-phase system in which the
melting endotherm of the drug and the glass transition temperature of the polymer are
obtained when the drug-polymer blend is subjected to DSC analysis. In type V solid
dispersions, the drug is transformed into amorphous state but is not molecularly dispersed
in the polymer matrix. In case of type VI, the solid dispersion of the drug is molecularly
dispersed in the polymer phase. This results in a single-phase system showing only one
glass transition temperature.
To better understand the difference in the thermodynamic properties of a
crystalline and an amorphous form, consider a crystalline drug that is heated to ceratin
temperature where it melts completely. Upon slowly cooling, the drug molecules form an
orderly system which is thermodynamically stable point on crystal lattice (3). However, if
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the cooling rate is high, then the drug molecules may attain a supercooled liquid state
without undergoing crystallization. On further cooling, a glass transition temperature (Tg)
is reached below which it converts into a frozen glassy state. A material in a glassy state
behaves like a brittle solid but without crystalline structure (4). The amorphous state of a
drug has a higher enthalpy, entropy and Gibbs free energy as compared with the
crystalline form. This is the reason why amorphous drug has higher apparent solubility.
When an amorphous drug is added to the dissolution media, the drug solubilizes rapidly
forming a supersaturated solution followed by a decrease in solubility due to
devitrification. This phenomenon is known as “spring and parachute effect” and creates
considerable challenges during dissolution. The choice of the polymeric carrier plays a
major role in maintaining the supersaturated solution and preventing the spring and
parachute effect during dissolution. Therefore, the selection of a polymeric carrier plays a
major role in the formulation of amorphous solid dispersions.
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Table 1: Various types of solid dispersions based on the physicochemical properties of
the drug and the carrier

Type of solid dispersion

Matrix

Drug

Phases

I. Eutectic

C

C

2

II. Amorphous precipitates in crystalline matrix

C

A

2

III. Solid solutions

C

M

1 or 2

IV. Glassy suspensions

A

C

2

V. Glassy suspensions

A

A

2

VI. Glassy solutions

A

M

1

**C – Crystalline; A – Amorphous; M – Molecularly dispersed
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1.2. Various Polymeric Carriers for ASDs
Polymers are repetitive structural units of monomers which are linked with each
other. They can be classified on the basis of their origin as natural, semisynthetic or
synthetic polymers (5). Polymers are classified as homopolymers (one type of monomer)
or a copolymer (two monomers). Polymers can be amorphous, semicrystalline or
crystalline. Since polymers have a complex 3-dimensional structure, incorporation of
amorphous drugs into the polymeric matrix hinders the molecular mobility of amorphous
drug, thereby preventing recrystallization over the shelf life of the product (6). The
physical and chemical stability of ASDs depend on various factors like molecular
mobility, thermodynamic properties, environmental stress, and method of preparation.
The polymeric carriers will effects these factors and stabilize the ASDs by four main
mechanisms:
 Crystallization inhibition
 Antiplastisization
 Intermolecular interactions
 Reduction of molecular mobility

1.2.1. Crystallization Inhibition
The crystallization of an amorphous drug is a 2-step process that occur
simultaneously. The first step is nucleation and occurs at a lower temperature, and the
second step is the crystal growth that requires higher temperatures (2). Thus, nucleation
may not start until a certain degree of supersaturation is reached to overcome the energy
barrier. The supersaturated concentrations where no nucleation occurs is known as the
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metastable zone. An ideal polymeric excipient increases the degree of supersaturation,
thus expands the metastable region. Polymeric excipients that increase aqueous solubility
can retard the nucleation rate by decreasing the free drug concentration available for
nuclei/ seed formation (7). Since polymeric carriers have sufficiently high configurational
entropy due to their large, complex, and flexible structures, they significantly reduce the
chance of drug recrystallization as it lowers the total Gibbs free energy of the amorphous
drug.

1.2.2. Antiplasticization
Antiplasticization is described as a phenomenon which leads to an increase in
glass transition temperature, Tg of the material. This results in an increase in the free
energy required by the amorphous drug to convert into the crystalline form (8). When
two materials having different Tg are mixed together, the final Tg of the mixture will be
somewhere between the Tg of both the materials. Mixing a low Tg amorphous drug with a
high Tg polymer at the molecular level leads to the formation of ASDs with a Tg
intermediate of these two components. In other words, the polymer undergoes
plasticization whereas the Tg of the drug increases, and it undergoes antiplasticization.
Sathigari et al. have studied the stabilization of amorphous efavirenz in Plasdone S-630
carrier (9). They have reported that the stability of the amorphous efavirenz in the solid
dispersion is due to the antiplasticizing effect of the polymer which increased the
viscosity of the system and decreased the diffusion of drug molecules.
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1.2.3. Intermolecular Interaction
The drug molecules may interact with polymers by several weak forces such as
hydrogen bonding, van der Waals forces, electrostatic, ionic, or hydrophobic interactions
(10). These intermolecular bonds restrict the molecular mobility of the drug molecules in
the polymer matrix and increases the physical stability of the drug-polymer system (11).
Meng et al. highlighted the importance of drug-polymer interactions in the stability of
amorphous curcumin as a model drug (12). They examined the ability of different
polymers, such as PVP K90, Eudragit EPO®, HPMC, and PEG 8000, to interact with the
model drug through stable bond formation. It was concluded that a certain degree of
interaction between a drug and a polymer is important for successful formulation of
ASDs. Maniruzzaman et al. have reported that the drug polymer ratio and miscibility
defines the magnitude of the intermolecular interactions (13).

1.2.4. Reduction of Molecular Mobility
The molecular mobility of amorphous materials determines their physical
stability. Polymeric carriers have the capacity to restrict the molecular mobility of the
amorphous API which can be determined using certain analytical techniques like
differential scanning calorimeter (DSC), solid-state nuclear magnetic resonance
(ssNMR), and dielectric spectroscopy. Knapik et al. have shown that the physical
stability and water solubility of the amorphous ezetimibe was improved over 6 times
when mixed within a ASD using Soluplus® as carrier (14). DSC and dielectric
spectroscopy analysis of amorphous ezetimibe have led to the conclusion that the high
molecular mobility, reflected in structural relaxation, is mainly responsible for its high
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crystallization tendency. This indicates that formation of ASDs in the Soluplus® matrix
acts as physical barrier to the molecular motions of glass ezetimibe leading to improved
stability. In another study, Kothari et al. reported that the relaxation time of the drug
increases with an increase in polymer concentration (15).

1.3. Preparation of ASDs using Hot Melt Extruion
The pharmaceutical industry is shifting from the traditional spray drying process
towards hot-melt extrusion for the preparation of solid dispersions. This is to reduce the
use of solvents and also to achieve the goal of continuous manufacturing. Hot-melt
extrusion (HME) has been revealed as a viable technology for variety of applications in
the pharmaceutical industry (16). The enhancement of solubility and bioavailability
through the manufacturing of ASDs is the primary use of HME, as indicated by the
multiple papers and patents. Current, interest in the formulation of ASDs using HME is
growing rapidly with a number of papers published in the scientific literature during the
past two decade (9, 17-19). Although there is a huge potential for formulating poorly
soluble drugs into ASDs, only a few commercial formulatiosn are available in the market
(Table 2).
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Table 2: List of marketed formulations of solid dispersions manufactured using HME

Product

API

Manufact
urer

Indication

Polymer

Norvir®

Ritonavir

Abbott

HIV

PEG-glyceride

Rezulin®

Troglitazone

ParkeDavis

Diabetes

PVP

Noxafil®

Posaconazole

Merck

Antifungal

HPMCAS

Onmel®

Itraconazole

Merz

Onychomycosis

HPMC

Kaletra®

Lopinavir/
Ritonavir

Abbott
Labs.

HIV

Copovidone

Merck

Insomnia

Copovidone

Belsomra® Suvorexant
Technivie
®
/
Viekirax®

Ombitasvir,paritap
AbbVie
revirand ritonavir

Hepatitis C
virus

Copovidone/vitamin
E-polyethylene
glycolsuccinate

Viekira
Pak®

Dasabuvir,
Ombitasvir,
Paritaprevir,
Ritonavir

AbbVie

Hepatitis C
virus

Copovidone

Venetoclax

AbbVie

Chronic
lymphocyticleu
kemia

Copovidone/polysor
bate80

Hepatitis C
virus

Copovidone/vitamin
Epolyethyleneglycol
succinate

Venclexta
®

Mavyret

®

Glecaprevir/pibren
AbbVie
tasvir
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This can be attributed to the poor understanding of the ASD formulations at the
molecular level and also the trial and error approach employed for HME (Fig. 1).
However, with an increase in the number of some high quality research in the field of
ASDs, more and more scientific data is available to understand the drug-polymer
interactions and the effect of the HME process on the performance of ASDs. This is
evident as more and more HME-based drug products appear in the pipeline of many
pharmaceutical companies. Lately, there have been new product submissions to the FDA
and to the European Medicines Agency (EMA) (19). In HME-based drug products, a
robust preformulation assessment is the key to a successful development. A step-by-step
approach, starting with the thermodynamic evaluation of several systems, followed by a
polymer screening test is useful to rapidly identify optimized HME formulations. The
three main aspects of developing ASDs are:
 Rationale selection of polymer
 Process design and optimization
 Stability testing
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Figure 1: Current approach in the formulation of amorphous solid dispersions and its
drawback
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1.4. Rationale Selection of Polymeric carrier
The rationale for the selection of polymer has been largely its glass transition
temperature (Tg), melt viscosity and dissolution rate. Polymers with high glass transition
temperature Tg are generally used to prepare ASDs owing to their antiplasticizing effect
that reduces the molecular mobility of amorphous drug. However, when there is no Tg
differences between amorphous drug and the solid dispersion, then the drug-polymer
interactions will determine the shelf life of ASDs (20). Increasing the molecular weight
raises the Tg of polymers which favors antiplasticization of amorphous drugs. Whereas, at
high molecular weight, the rise in Tg becomes insignificant as other factors such as
viscosity come into play during the dissolution process. Viscosity of polymers increases
with molecular weight which has significant effect on the dissolution properties. Once the
polymers are selected, they are further screened based on the miscibility with the drug
which is determined by film-casting method. It involves mixing the drug and polymer in
a common solvent and then applying the solution as a film. Once the solvent is
evaporated, the film is then analyzed under hot-stage microscopy to observe the presence
of phase separation. However, this approach is applicable only in processes such as spray
drying where a solvent is used. In the case of hot melt extrusion, the drug and polymer
are directly in physical contact with each other without the presence of a solvent. Their
molecular mobility is less and depends on the processing temperature. Therefore, results
obtained from film-casting method are often overestimated compared to the actual results
obtained from hot-melt extrusion. This shows that there is a need to develop a robust
methodology with the use of minimum material to successfully formulate solid
dispersions. Different methods such as solubility parameter approach, Flory-Huggins
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theory and melting enthalpy approach as preformulation tools for the rational selection of
polymers have been reported in the literature.

1.4.1. Solubility Parameter Approach
Solubility parameters are the numerical values that represent the dispersive, polar
and hydrogen bonding forces in a molecule. They are calculated based on the functional
groups present in the chemical structure of a molecule and they contribution to various
intermolecular forces. These intermolecular forces were calculated using various group
contribution methods, viz. Hoftyzer and Van Krevelen, Hoy, Small, Dunkel, Hayes, and
Di Benedetto (21). Generally, drug polymer systems with similar solubility parameter
values are predicted to be more miscible. Drug-polymer mixtures with the solubility
parameter difference, Δδ < 7.0 MPa1/2 are found to be miscible whereas systems with Δδ
> 10.0 MPa1/2 are likely to be immiscible (22). Estimation of drug-polymer miscibility
based on the difference in the solubility parameter values is still one of the most applied
approaches in the academia and pharmaceutical industry owing to its relative simplicity.
Just et al. discussed about various attempts to improve group contribution parameters and
to develop new values based on solids (23). Wlodarski et al. reported the use of the
solubility parameters for the prediction of miscibility between itraconazole and two
polymers, polyvinyl alcohol and copovidone (24). Pawar and co-workers used Hansen
solubility parameters to predict the miscibility of efavirenz in polymers for the
preparation of ASDs using HME (25). Although the solubility parameter can be useful
for the fast screening of polymers, it often leads to the exclusion of good polymeric
candidates. Therefore, additional experimental work is required to confirm the
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interpretations obtained using solubility parameter approach. Recently, Turpin et al.
experimentally determined the miscibility of various model drugs and the results were
compared with that of the results predicted using Hansen solubility parameters approach.
(26). The study showed that the predicted results from the solubility parameters did not
match the experimental data. The authors attributed this to the negligence of not
considering the intermolecular interactions in the solubility parameter approach. To
address these drawbacks, more complex methods were introduced to predict the drugpolymer miscibility. One of these methods is the calculation of the Flory–Huggins
interaction parameter (χd-p), usually through the application of the melting point
depression (MPD) theory.

1.4.2. Melting Point Depression Theory
The most widely used method for the estimation of drug solubility in a polymer is
by using the melting enthalpy of the crystalline drug in a drug-polymer system measured
by DSC. This method is based on a simple principle that the fraction of drug dissolved in
the polymer does not contribute to the melting endotherm. Therefore, by measuring the
melting enthalpy of a series of drug concentrations in drug-polymer mixtures and
extrapolating the plot to zero enthalpy, the solubility of a given drug in selected polymers
can be estimated from the x-intercept of the plotted line.
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1.4.3. Flory-Huggins Theory
Flory-Huggins (F-H) theory is a well-known lattice-based theory which describes
polymer-solvent miscibility on the basis of the Gibbs free energy change associated with
the mixing of a polymer in a solvent (27). Recently, this theory was applied for assessing
drug-polymer miscibility using the melting point depression method to obtain F-H
interaction parameter, χd-p (22). A negative value of χd-p indicates stronger drug-polymer
interaction than individual drug-drug or polymer-polymer interaction which predicts
drug-polymer miscibility, whereas a positive value indicates that homonuclear
interactions are preferred over heteronuclear interactions which may lead to phase
separation (28). This method is also used by the pharmaceutical industry and is probably
the most popular approach, with research work published by many reputed
pharmaceutical companies. Earlier, the assessment of acetaminophen and naproxen
solubility in polymeric excipients, such as povidone and co-povidone, calculated with
three models including F-H equation, was published by Lehmkemper and co-workers
(29). The results were in line with the experimental solubility data. However, the F-H
theory underestimated the effect of acetaminophen miscibility on stability.

1.4.4. Thermodynamic Phase Diagrams
Another common tool within the industry is the construction of phase diagrams
which are usually based on the F-H theory. Phase diagrams depict the relationship
between the free energy and drug loading. The use of phase diagrams have been
described extensively in the literature (27,28,30,31). Still, phase diagrams are
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temperature dependent, and an immiscible system can, therefore, become miscible if the
temperature increases.

1.5. Hot Melt Extrusion Process Optimization
Once a suitable polymer is selected for the formulaton of ASDs, the next
challenge is to determine the optimum formulation and process parameters. When
choosing a commercial ASDs manufacturing process, there are two leading choices:
spray drying or hot melt extrusion (HME). Although solvent-based processes are more
common because they are applicable to a wide range of compounds, HME offers several
advantages for thermally stable systems. It is solvent-free, continuous, high-throughput,
easily scalable and inexpensive. Avoidance of thermal degradation and an absence of
residual crystallinity are two critical quality attributes of hot melt extruded ASDs (36,
37). To avoid thermal degradation of drug and/or polymer, lower processing temperatures
are desirable, although accompanied by a risk of residual crystalline content if the
crystals do not fully melt or dissolve during the process. Various studies have reported
the HME processing at temperatures below the drug’s melting point utilizing melting
point depression phenomenon (38, 39). Studies providing strategies to mitigate the
corresponding risk of crystallinity have thus far been limited to equipment setup like
screw configuration and drug particle size reduction (18). Physical instability and
dissolution performance are affected by many parameters, such as drug loading, polymer
type, miscibility, Tg and the inherent crystallization tendency of the drug and may be
accelerated by the presence of seed crystals (36–39). Therefore it is considered critical to
design the ASD manufacturing process to generate a fully amorphous system. In light of
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the FDA encouraging Quality by Design (QbD) practice for all the formulations,
applying it in the case of ASDs seems challenging (40). This is due to various factors that
effect the characteristics of ASDs. However, once the maximum drug loading was
determined using preformulation studies, the process parameters can then be optimized
using a suitable experimental design. Since fully amorphous systems are considered
stable, it is significant to determine the maximum solubility of the drug in the polymeric
carrier. The thermodynamic phase diagram has been conceptually proposed in the
literature as a methodology for identifying the maximum solubility of the drug in the
polymeric carrier as well as the processing temperature (36, 39). A typical
thermodynamic phase diagram shown in Figure 2 consists of a solubility curve, a
miscibility curve and a glass trasition curve.
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Figure 2: Typical thermodynamic phase diagram consisting of a solubility curve, a
miscibility curve and a glass transition curve
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Most of the research in the field of HME is limited to a simple experimental
design which fails to determine the interaction effect between the CMAs and the CQAs
on the CMAs. Since HME is a complex process with various interaction effects, it is ideal
to study the process using a design that better helps understand the effect of various
CQAs and CPPs on the CMAs. However, it is challenging to perform enough
experimental runs using HME, especially during initial phase of development due to
limited availability of the drug. Therefore, material sparing techniques are necessary to
speed up the formulation development process using HME. One such technique is DSC, a
commonly used thermal analysis instrument. It is similar to HME in the case of heat
conduction except the absence of mechanical stress. However, when the particle size of
drug and polymer blend is reduced significantly, then the thermal events in the DSC and
HME are comparable. Apart from that, DSC requires small quantity of material and the
samples subjected to thermal analysis can be retrived and analyzed. Phase diagrams
coupled with DoE could provide useful information regarding formulation and process
optimization.

1.6. Physical Stability of ASDs
The amorphous drug–polymer dispersion is commonly characterized in terms of
physical properties such as glass transition temperature (Tg), heat capacity, and
miscibility (45, 46). Though it is widely regarded that an increase in Tg indicates the
improvement of physical stability, there is no direct evidence disclosed to relate Tg to
recrystallization activation energy, the critical parameter evaluating stability. Tg is not an
intrinsic property and contingent to prior thermal history. Methods involving Tg
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measurement therefore are ambiguous. Some studies experimentally proved the
surprising occurrence of nucleation below Tg indicating that Tg is not a reliable indicator
of physical stability (41, 47). Recrystallization kinetics is a mathematical model which
has a potential to estimate the physical stability of ASDs. The model is based on the
approximation of the nucleation and crystal growth contributions which are inherently
essential to an accurate prediction of the physical stability of ASDs. This approach was
first introduced by Avrami and is the commonly used model to estimate the
crystallization kinetics for decades (48, 49). However, the reliability and accuracy of this
equation is compromised because of its critical oversimplifications, most notably that the
nucleation rate is constant throughout the recrystallization process. Other models also
have been developed based on solid state reaction kinetics (46–49), however, there has
been little progress in their application to stability prediction of pharmaceutical solid
dispersion. Most recently, a new kinetics model was developed by Yang et al. by
correcting the critical oversimplification on nucleation rate in the Avrami equation (50).
However, further studies need to be done to validate the applicability of the kinetic model
to determine the shelf life of ASDs.

1.7. Need to Restructure the Formulation Approach for ASDs
A systematization of a rational approach to design solid dispersions is crucial for
a successful, fast and low-cost development, which avoids promising formulations being
prematurely eliminated from experimental studies. The most common approaches for
screening excipients for HME formulations are based on solvent evaporation methods,
DSC analysis, hot stage microscopy (HSM) and melt-based methods. Solvent-
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evaporation methods are probably the most common in the industry setting, because of
their simplicity and low cost. Some studies have been published, describing ways of
automating and miniaturizing the screening of excipients in a high-throughput manner
(51–53). However, DSC studies, HSM or melt-based methods have the advantage of
applying heat which can be beneficial when the manufacturing process under study is
HME. Auch and co-workers noticed discrepancies between a solvent-based screening
method and experimental results for ASDs (54). Based on the literature a structured
screening approach for the formulation of ASDs is presented in Figure 3. This
methodology reflects the usual techniques, based on physicochemical principles and
thermodynamic assessment of the drug and the polymer, with the aim of maximizing
success rates and reducing risks. One of the main advantages is including the assessment
of physical stability at the early stages during product development. This approach is
divided into four stages. During the first stage, an in-depth evaluation of physicochemical
properties of the drug and potential polymers is performed. Then, in the second stage,
excipients are assessed through solubility parameters, melting point depression and
Flory-Huggins interaction parameter. This preliminary evaluation can be complemented
with experimental tests, such as DSC, where depression of the melting point evaluated
and, eventually, the interaction parameter can be calculated. As an outcome, excipients
with a high probability of miscibility and chemical interaction are taken to the third stage
where the process optimization is done using the thermodynamic phase diagrams and a
material sparing DSC method. The results from the DSC method is validated using
samples prepared by vaccum compression molding (VCM) and HME. In the final stage,
the kinetic stability of the ASDs is predicted using a kinetic model.
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Figure 3: Proposed approach for early formulation development of ASDs by HME
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2. Study Objectives
The objective of the present study was to develop various material-sparing preformulation tools for rapid formulation development of ASDs. To achieve this, various
specific objectives were proposed which are as follows:

1. To estimate the drug-polymer miscibility using solubility parameter approach and
melting point depression method and to compare the results from both the
approaches.
2. To estimate the ideal drug loading and ideal processing temperature for HME using
thermodynamic phase diagrams and Gibbs free energy plots.
3. To develop a material-sparing method based on differential scanning calorimeter
(DSC) to determine the design space for hot melt extrusion.
4. To predict the physical stability of ASDs at various temperature and relative
humidity conditions using modified Avarami equation.
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3. Materials and Methods
3.1. Model Drug: Mefenamic acid
Mefenamic acid was selected as a model drug based on its physicochemical
properties. It is a BCS class II drug with poor water-solubility and high permeability. It
has a pKa value of 4.2 making it a weakly acidic drug. The rationale for the selection of
mefenamic acid was its high melting point of 230 - 231 °C and its tendency to degrade
upon melting. This makes it a challenging drug to process using thermal techniques, i.e.
hot-melt extrusion. There are three polymorphic forms reported for mefenamic acid.
Form III is the metastable form which transforms into form I at ambient conditions and
into form II at elevated temperatures (55). The saturated solubility of form II is more
than form I, however, in the dissolution media, form II rapidly converts into form I.
Therefore, the rate of conversion of form II into form I is the rate-limiting step in the
dissolution of mefenamic acid. For the current study, mefenamic acid was purchased
from Alfa Aesar (Haverhill, MA)

3.2. Model Polymers
Four model polymers, i.e. Eudragit® EPO (EPO), Kollidon® VA 64 (VA 64),
Soluplus® (SLP) and Pluronic® F68 (F 68) were used as polymeric carrier materials.
Eudragit® EPO was a kind gift from Evonik Corp. (Parsippany, NJ). Soluplus®,
Pluronic® F68 and Kollidon® VA64 were kind gifts from BASF Corp. (Florham Park,
NJ). These polymers were selected based on their glass transition temperature, Tg,
solubilization capacity, hygroscopicity and toxicity profile. These four polymers differ in
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their chemical composition and ionic nature; F68 is a non-ionic, EPO is a cationic, and
SLP and VA64 are amphoteric polymers in nature. These polymers have similar
solubility parameters to that of the drug MFA but differ in their chemical structure. This
helps to understand the role of solubility parameter in predicting the drug-polymer
miscibility.

3.3. Physicochemical Evaluation of Drug and Polymers
3.3.1. Determination of Melting Temperature, Tm
The melting temperature of drug and polymers were determined using a
differential scanning calorimetry (DSC 6000, Perkin Elmer, USA) which was calibrated
using indium standard prior to analysis. During analysis, accurately weighed,
approximately 10 mg of material was taken in an aluminum sample pan and thermal runs
were conducted over a temperature ranges of 30° to 250 °C, depending on the melting
point of the material reported in the literature. A heating rate of 5 °C/min and nitrogen
gas flow rate of 50 mL/min were maintained. The endpoint of the melting endotherm
was taken as the melting point of the material.

3.3.2. Determination of Degradation Temperature, Td
The degradation temperature of the drug and the polymers were determined using
a thermogravimetric analyzer (PyrisTM 1 TGA, Perkin Elmer, USA). The temperature
calibration of the instrument was performed using nickel Cure point method before
analysis. Accurately weighed, approximately 10 mg of material was placed on a
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platinum sample pan and thermal run was conducted over a temperature range of 30° to
270 °C. A heating rate of 5 °C/min and nitrogen gas flow rate of 50 mL/min were
maintained during analysis. The percent degradation was calculated from the difference
in the initial and the final weight of the sample.

3.3.3. Determination of Glass Transition Temperature, Tg
The glass transition temperatures, Tg, of the drug and the polymers were
determined using differential scanning calorimetry (DSC 6000, Perkin Elmer, USA).
Accurately weighed, approximately 10 mg of material was placed and sealed in an
aluminum sample pan. The sample pan was equilibrated at 30°C for 1 min and heated to
240°C at 5°C/min rate and modulation of 1°C/min. The Tg of the drug and the polymers
were determined using PyrisTM Manager software (Perkin Elmer, USA).

3.3.4. Determination of True Density, ρ
True density of the powder materials was determined using a gas pycnometer
(AccuPyc® II 1340, Micromeritics Instruments Corp., Norcross, GA). Prior to analysis,
the pycnometer was calibrated with an iron sphere of known mass prior to each
measurement. During analysis, a known weight of powder sample was transferred into
an aluminum sample container of 3.5 cm3 volume, and helium gas was passed through
the sample from the reservoir. The determinations were carried out at room temperature.
The instrument automatically purges moisture and volatile materials from powder sample
and repeats the analysis until successive measurements yield consistent results. The
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determination of sample density was repeated for up to 10 cycles. The average reading of
10 cycles was recorded as the true density of the material (56–59).

3.4. Solubility Parameter Approach
3.4.1. Calculation of Hildebrand Solubility Parameter, δ
The calculation of the Hildebrand solubility parameter of a chemical is based on
the cohesive energy density of the functional groups in its molecule. Cohesive energy
density is expressed as the cohesive energy, ∆Ev, of the molecules per unit volume, V.
The Hildebrand solubility parameter is then calculated as the square root of the cohesive
energy density of the molecule according to eq. (1). The values of the ∆Ev and V of the
functional groups were adapted from Fedors (60).

δ = CED. = (∆E ⁄V).

(1)

3.4.2. Calculation of Hansen Solubility Parameters, δt
The Hansen solubility parameter is a modification of the Hildebrand method in
which the cohesive energy is divided in three different forces, i.e. dispersion, polar and
hydrogen bonding forces. The Hansen solubility parameter is expressed as δt, and its
value is calculated using the following equation (Eq. 2):

δ = δ + δ + δ

(2)
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Where δd, δp and δh are the dispersion forces, polar forces, and hydrogen bonding forces,
respectively, in a molecule that are calculated using the following relationships:

δ =

∑ 


;

δ =

∑ 


;

δ = 

∑ 


(3)

The chemical structure of a molecule was divided in different functional groups
and the values of Fdi, Fpi and Ehi were calculated according to the group contribution
method by Van Krevelen-Hoftyzer for each functional groups in a molecule (61). The
value of molar volume, V was calculated according to Fedors (60).

3.4.3. Construction of Bagley’s Plot
Bagley et al. introduced the combined solubility parameter, δv, based on the
thermodynamic considerations that dispersion forces, δd, and polar forces, δp, show
similar effect, whereas the effect of δh is different (62). The combined value of the
solubility parameter, δv was calculated according to eq. (4):
δ = δ + δ

(4)

Bagley’s plot was constructed using the relationship between δv and δh which
helps to project the three-dimensional solubility parameters into a two-dimensional plot.
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3.4.4. Estimation of F-H interaction parameter, χ
The Flory–Huggins interaction parameter between the drug and the polymers, χd-p
was estimated using the solubility parameters of drug, δdrug and polymer, δpolymer
according to the following equation:

χ = V

   




(5)

Where χd-p represents the F-H interaction parameter between the drug and the polymer, V
is the molar volume calculated according to the group contribution method from Fedors
(60). R is the universal gas constant (8.314 J/mol.K); T is the temperature in Kelvin
(293.1 K).

3.5. Melting Point Depression Method
3.5.1. Preparation of Drug-Polymer Physical Mixtures
The drug-polymer physical mixtures were prepared by accurately weighing
various ratios of drug and polymer and then gently mixing them together to form a
homogenous mixture using a mortar and pestle. Care was taken not to apply excessive
mechanical stress on the mixture that could result in the amorphization of the drug.

3.5.2. Determination of Melting Point of MFA
The melting point of the mefenamic acid in drug-polymer mixtures was
determined using a differential scanning calorimetry (DSC 6000, Perkin Elmer, USA).
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Accurately weighed, approximately 10 mg of the drug-polymer mixture was taken in an
aluminum sample pan and thermal runs were conducted over a temperature range of 30°
to 250 °C at a heating rate of 5 °C/min under nitrogen gas flowing at the rate of 50
ml/min. The endpoint of the melting endotherm was taken as the melting point of the
drug. To ensure content uniformity, several samples were analyzed for each drugpolymer ratio and only three samples (n=3) with the heat of fusion, ∆Hf, values of less
than ±5% variation from the theoretical value were used for analysis.

3.5.3. Estimation of Drug-Polymer Interaction Parameter
The drug-polymer interaction parameter, χ, was estimated using the melting point
depression using the following equation (Eq. 6):





−









= − ∆ lnϕ + 1 −  ϕ + χϕ 


(6)

Where Tm is the melting point of drug-polymer mixture (K); Tmo is the melting
point of pure drug crystal (K); R is the real gas constant (8.314 J/mole K); ∆Hf is the heat
of fusion of the drug (kJ/mol), ɸd is the volume fraction of the drug, ɸp is the volume
fraction of the polymer, χ is the drug-polymer interaction parameter, and m is the degree
of polymerization of the polymer which is the ratio of the volume of a polymer chain to
drug molecular volume. It was calculated using the following equation (Eq. 7):

m=

()

()


(7)
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where the Mw(polymer) and Mw(drug) are the molecular weight of polymer and drug,
respectively, and the ρpolymer and ρdrug are the density of polymer and drug, respectively.

3.5.4. Establishing Relationship Between Interaction Parameter, χ and
Temperatures
The interaction parameter, χ between drug and polymer is temperature dependent.
The value of χ estimated using the melting point depression method is clost to the melting
temperature of the drug. To estimate the Gibbs free energy of mixing at various
temperatures, the value of χ at various temperatures was estimated. This was done by
determining the temperature dependence of the interaction parameter, χ using the
following equation:

=+




(8)

Where A is the entropic contributions, and B is the enthalpic contributions for
mixing. These constants are used to theoretically calculate the value of χ at any specific
temperature.

3.6. Construction of Gibbs Free Energy Plots
The Flory-Huggins theory relates the Gibbs free energy of mixing the drugpolymer mixtures with the drug-polymer interaction parameter (χ) according to the
following equation:
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∆G = RT ϕ ln ϕ +




ln ϕ + χ ϕ ϕ 

(9)

The value of the interaction parameter, χ at various temperatures was determined from
eq. (8). These values were then used to estimate the Gibbs free energy of mixing (∆Gmix)
at various temperatures.

3.6.1. Validation of Gibbs Free Energy Plots
The Gibbs free energy plots constructed using the Flory-Huggins theory were
validated using a hot stage microscope (FP82HT, Mettler-Toledo, Greifensee,
Switzerland) equipped with a Nikon Eclipse 50i microscope (Nikon Inc., Tokyo, Japan)
with a 10x cross-polarized lens. A 1:1 ratio of the drug and the polymer was dispersed in
acetone and transferred onto a glass slide. This step ensured that the drug and the
polymer were mixed thoroughly. After evaporation of the organic solvent, the samples
were heated on the hot stage microscope from 30° to 230 °C at 10 °C/min rate and the
changes in the drug crystal morphology as a function of temperature were recorded using
a Nikon digital single-lens reflex camera attached to the microscope. The onset
temperature where the drug crystals were completely miscible in the polymeric matrix
was recorded and compared with the results obtained from the Gibbs free energy plots.

3.7. Construction of Thermodynamic Phase Diagrams
A binary phase diagram depicts the maximum solubility and miscibility of an
amorphous drug in the polymeric carrier as a function of temperature. It consists of a
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drug-polymer solubility curve, drug-polymer miscibility curve and the glass transition
curve of the drug-polymer system.

3.7.1. Estimation of Solubility Curve
The solubility curve refers to the temperature at which the crystalline drug is in
equilibrium with the dissolved or dispersed drug in the polymeric matrix. Marsac et al.
proposed an approach for the estimation of the drug-polymer solubility that was based on
the Flory-Huggins lattice theory (42). According to the authors, the mole fraction
solubility of a drug in the polymer is related to the activity coefficient of the drug and the
interaction parameter between the drug and the polymer as expressed by the following
equation (Eq. 10):



ln γ x = ln ϕ + 1 −  ϕ + χ ϕ

(10)

Where xdrug is the mole fraction of the drug dissolved or dispersed in the polymer,
γdrug is the activity coefficient of the drug in the polymer, ϕdrug is the volume fraction of
the drug, ϕpolymer is the volume fraction of the polymer, and m is the ratio of the volume
of the polymer to the volume of the drug.
Another approach to determine the temperature at which the crystalline drug is in
equilibrium with the dissolved or dispersed drug in the polymeric matrix is using the
following solid-liquid equilibrium (SLE) equation (Eq. 11):
∆

lnx =  1 −






 − lnγ

(11)
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Where xdrug is the mole fraction of the dissolved drug,  is the activity
coefficient of the drug, T is the temperature of the two phases of the drug in equilibrium
(K),  is the melting point of pure drug crystal (K), R is the real gas constant (8.314
J/mol.K), and ∆Hf is the heat of fusion of the drug (kJ/mol).
The value of activity coefficient, γdrug, of the drug can be calculated using the
extended Hansen solubility model (Eq. 12):

ln γ =






δ





− δd + 0.25 δ





− δp + δ



− δh  + ln




+1−




(12)

Where V is the molar volume of the drug, δ is the Hansen solubility parameter, 

is the molar volume-weighted Hansen solubility parameter, and  is the mixture volume.
The subscripts, d, p and h, stand for dispersion, polar and hydrogen-bonding forces,
respectively.
The values of mixture volume and molar volume-weighted Hansen solubility
parameter can be calculated using the following equations:
 ̅ = ∑  
 =

 



 = ∑  

(13)

(14)

(15)

Where ϕ is the volume fraction, x is the mole fraction, M is the molecular weight,
ρ is the density, and the subscript k denotes the different components of the mixture.
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3.7.2. Estimation of Miscibility Curve
The drug-polymer miscibility curve is also called as the spinodal decomposition
curve that defines the boundary between the unstable zone and the metastable zone in the
drug-polymer mixture. It is plotted by equating the second derivative of the free energy
to zero as expressed below (Eq. 16):
T =





()

(16)

Where, ϕ is the volume fraction of the drug calculated using the true density of
the drug and polymer, 1-ϕ is the volume fraction of the polymer, and m is the degree of
polymerization of the polymer which is the ratio of the volume of a polymer chain to
drug molecular volume. The constants A and B are obtained by the melting point
depression data obtained using eq. (8).

3.7.3. Estimation of Glass Transition Curve
The glass transition temperatures, Tg, of the drug and the polymers were
determined using differential scanning calorimetry (DSC 6000, Perkin Elmer, USA).
Accurately weighed, approximately 10 mg of material was placed and sealed in an
aluminum sample pan. The sample pan was equilibrated at 30°C for 1 min and heated to
240°C at 5°C/min rate and modulation of 1°C/min. The Tg of the drug and the polymers
were determined using PyrisTM Manager software (Perkin Elmer, USA). The glass
transition temperature, Tg, of drug-polymer mixtures was predicted using the following
Gordan-Taylor equation (Eq. 17) .
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T =

 ,  , 
(  )

 

K=

 

(17)

Where, w1, Tg and ρ are the weight fraction, the glass transition temperature, and
true density of drug and polymer, respectively.

3.8. Material Sparing DSC Method for Process Optimization of HME
3.8.1. Analytical Techniques
3.8.1.1. Differential Scanning Calorimeter
A differential scanning calorimeter (DSC 6000, Perkin Elmer, USA) was used to
determine the melting endotherm of crystalline drug, MFA. The instrument was
calibrated using indium standard before analysis. Accurately weighed, approximately 15
mg of MFA was placed and sealed in an aluminum sample pan (50 µL) and heated over a
temperature range of 30° to 250 °C at a heating rate of 1 °C/min to 10 °C/min under
nitrogen gas flowing at the rate of 50 ml/min. The final heating temperature and the
heating rate were changed according to the experimental design. The changes in the
melting endotherm of MFA was recorded using PyrisTM Manager software (Perkin Elmer,
USA).

3.8.1.2. Thermo Gravimetric Analysis
The thermal degradation of MFA was determined using a thermogravimetric
analyzer (PyrisTM 1 TGA, Perkin Elmer, USA). The temperature calibration of the
instrument was performed using the nickel Curie point measurement method before
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analysis. Accurately weighed, approximately 10 mg of pure MFA was placed in a
platinum sample pan and a thermal run was conducted over a temperature range of 30° to
250 °C at various heating rates from 0.5 °C/min to 15 °C/min under nitrogen gas flowing
at the rate of 50 ml/min. The heating rate was changed according to the experimental
design. The percent weight loss was calculated from the difference in the initial and final
weight of the sample using PyrisTM Manager software (Perkin Elmer, USA).

3.8.1.3. High Performance Liquid Chromatography
The amount of MFA in the samples was determined by carefully diluting them
with mobile phase consisting of 46:40:14 ratio of acetonitrile, buffer solution (50 mM
solution of monobasic ammonium phosphate adjusted with 3 M ammonium hydroxide to
a pH of 5.0) and tetrahydrofuran. The diluted samples were then analyzed using a highperformance liquid chromatography (HPLC) system (Agilent Corporation, USA)
equipped with an autosampler (AS2055 Plus, intelligent sampler, JASCO Corp, Japan)
and photodiode array detector (JASCO Corp., Japan). A Phenomenex Luna® reversed
phase C18 column (150 × 4.6 mm; 5 μm particles) was used as a stationary phase. The
flow rate was 1.5 mL/min. with an injection volume of 20 μL and the detection
wavelength of 224 nm.

3.8.1.4. X-Ray Powder Diffraction (pXRD)
The presence of MFA crystals in the samples was determined by powder X-ray
diffraction (pXRD) analysis using X-ray diffractometer (Shimadzu 6000, Shimadzu
Corporation, Kyoto, Japan) which was calibrated using a quartz standard prior to
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analysis. During analysis, the drug-polymer dispersions were placed uniformly on a glass
sample holder to obtain a smooth and uniform surface. The samples were analyzed
through a CuKa, monochromatic radiation source emitting X-ray radiation with generated
voltage of 40 kV and current of 30 mA at room temperature. The diffraction patterns of
samples were obtained by scanning over a continuous 2θ range of 10–50° at a rate of 2
degree/min using a scan step size of 0.02 degree (63).

3.8.2. Initial Screening to Set up Experimental Design
Initial screening was performed to determine the study range for the experimental
design. Film casting method was used to determine the maximum drug-polymer
miscibility. Then, the minimum temperature at which the drug-polymer blends were
completely miscible was determined using hot stage microscopy. Later, TGA analysis
was performed at various heating rates to determine the temperature at which complete
degradation of MFA occurs in the drug-polymer powder blends.

3.8.2.1. Determination of Maximum Drug-Polymer Miscibility Using Film Casting
Method
The maximum miscibility of MFA in EPO was determined using film casting
method. Various powder blends with MFA:EPO ratios from 1:1 to 1:4 was dissolved in
enough quantity of acetone to form a clear solution. The resulting solutions were poured
in aluminum pans and the solvent was evaporated at 50 °C. Once the solvent evaporated,
the drug-polymer films were observed under a Nikon Eclipse 50i Microscope (Nikon
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Inc., Tokyo, Japan) using 10x cross polarized lens to detect the presence of any
crystalline MFA. The maximum drug loading at which no crystalline MFA was observed
in the films was used for further analysis.

3.8.2.2. Determination of Minimum Temperature of Miscibility (MTM) Using Hot
Stage Microscopy
The minimum temperature of miscibility (MTM) is the minimum temperature at
which the drug crystal completely gets miscible in the polymeric carrier. To determine
MTM, the powder blends of MFA and EPO corresponding to the maximum drugpolymer miscibility (determined from film casting method) were prepared using a mortar
and pestle. The powder blend was then heated on a hot stage (Mettler-Toledo FP82HT,
Greifensee, Switzerland) equipped with a Nikon Eclipse 50i Microscope (Nikon Inc.,
Tokyo, Japan) using 10x cross polarized lens. A small amount (2-4 mg) of sample was
placed on a glass slide with a cover glass and heated from 30 to 250 °C at 10 °C/min.
Changes in the samples morphology were recorded as a function of temperature using a
Nikon digital single-lens reflex camera attached to the microscope which were then
analyzed to determine the minimum temperature at which the MFA crystals got
completely miscible in the EPO matrix.

3.8.2.3. Determination of the Relationship Between Heating Rate and Drug
Degradation Using Thermogravimetric Analysis (TGA)
The heating rate and the final heating temperature for the experimental design was
determined using TGA analysis. The powder blends of MFA and EPO corresponding to
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the maximum drug-polymer miscibility were heated in TGA. Briefly, 10 mg of drugpolymer physical mixture was placed in a platinum sample pan and heated from 30° C to
250° C at various heating rates from 0.5 °C/min to 15 °C/min. The percent weight change
in the samples were analyzed using PyrisTM software V 8.0 (Perkin Elmer, USA). A
relationship between the % weight loss and the TGA heating rate was established to
determine the ideal heating rate for the experimental design.

3.8.3. Box-Behnken Experimental Design
In the present study, a Box-Behnken experimental design was used to study the
effects of independent factors on the dependent factors (responses). The experimental
design consisted of three independent factors, viz. drug loading (X1), heating rate (X2),
and processing temperature (X3). These factors were studied at three levels, i.e. low,
medium and high (-1, 0, +1). Out of the three factors, two factors were varied through the
four possible combinations of low-high, while one factor was kept constant resulting in
twelve experiments. The center point consisted of all the three factors at medium level
and was peformed in triplicate to identify any manual errors during experimentation. In
total, the Box-Behnken experimental design consisted of fifteen experimental runs
(twelve blocks and three center point). The levels of independent factors for the
experimental design were determined from the initial screening experiments using film
casting method, hot stage microscopy and TGA.
As per the applied design, the relationship between controlled input variables with
the responses was quantified and the true functional relationship was established. Usually
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a second order polynomial equation is used in response surface methodology to describe
the model which is as follows (Eq. 18) (64):

Y = B0 + B1X1 + B2X2 + B3X3 + B11X21 + B22X22 + B33X23 + B12X1X2 + B23X2X3 +
B13X1X3

(Eq. 18)

where Y is the level of predicted or measured response, B0 is the model constant or
intercept, X1, X2 and X3 are independent variables, B1, B2 and B3 are linear coefficients,
B12, B23 and B13 are interaction terms between independent variables or cross-product
coefficients, and B11, B22 and B33 are quadratic coefficients.
The dependent or response parameters selected for the study were residual
crystallinity (Y1) and drug loss degradation (Y2). This design allowed estimation of the
main factors and the interaction effects between the considerable independent parameters
(40). The relationship of between the independent parameters on the dependent
parameters was demonstrated by response surface plots with regions of maxima (red) and
minima (blue). A commercial software (Design Expert, version 11, Stat-Ease Inc.,
Minneapolis, MN) was used to generate the Box-Behnken design matrix and to analyze
the experimental data.

3.8.4. Preparation of Drug-Polymer Dispersions Using DSC
The drug-polymer physical mixtures were prepared according to the experimental
design using a mortar and a pestle. Around 20 mg of the physical mixture was heated
using a differential scanning calorimeter (DSC 6000, Perkin Elmer, USA) in a 50 µL
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aluminum sample pan. The heating rates and final heating temperatures were maintained
according to the experimental design. In order to ensure the content uniformity in the
physical mixtures, the heat of fusion, ∆Hf, of the melting endotherm of MFA was
compared to that of the pure crystalline drug. All the samples were stored in a desiccator
for 24 hrs before characterization. A total of six samples were prepared at each
experimental condition (n=6).

3.8.5. Determination of Residual Crystallinity of Drug using DSC
The residual crystallinity represents the percent of the total drug which remained
in the crystalline form in a sample. It was calculated according to the heat of fusion
values using following equation (Eq. 19):
Residual crystallinity (%) =

∆()

∆()

× 100

(19)

The observed heat of fusion value, ΔHf (observed), was experimentally determined by
heating the drug-polymer samples in a DSC at a rate of 5 °C/min from 30 °C to 230 °C.
The ΔHf value was then computed as the area under the melting endotherm using Pyris
software. The theoretical value of heat of fusion, ΔHf (Theoretical) (J/g) depends on the drug
load and the heat of fusion of pure mefenamic acid, ΔHf (Pure drug), (134.0 J/g) was
calculated using the following equation (Eq. 20):
∆H () =

  (%)


× ∆H ( )

(20)
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3.8.6. Determination of Drug Degradation Using HPLC
The drug degradation indicates the percent of the drug that degraded during
heating cycle. It was determined by carefully diluting the drug-polymer dispersions from
the DSC sample pans with the HPLC mobile phase. The diluted samples were then
analyzed using HPLC and the area under the curve (AUC) values of the degradation peak
and the drug peak were calculated using Agilent software (Agilent Corporation, USA).
The percent degradation was then calculated using the following equation (Eq. 21):
()

Drug degradation (%) = ()

 ()

Χ 100

(21)

3.8.7. Statistical Analysis
Multiple regression analysis of the experimental data was performed using Design
Expert software, version 11 (Stat-Ease Inc., Minneapolis, MN). The experimental data
were fitted in the second-order quadratic polynomial model along with added interaction
terms. The model was analyzed based on the values of R2, adjusted R2 (Adj. R2),
predicted R2 (Pred. R2), standard deviation (SD) and coefficient of variation (% CV).
ANOVA was performed to determine if the independent parameters had significant effect
on the response variables. The sum of squares (SS) and the mean square values of the
model and the residuals were calculated and the significance of the independent
parameters on the response variables was determined based on the F-value and P value.
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The ability of the model to predict all the response variables was determined by
calculating the values of lack of fit and the pure error.

3.8.8. Selection of Optimum Experimental Conditions
The selection of the optimum experimental conditions was carried out using both
numerical and the graphical optimization. The target values of residual crystallinity and
drug degradation were set at 15% and 5%, respectively to determine the optimum
experimental conditions. The numerical optimization was performed to determine all the
possible combinations of the independent parameters that result in the response variables
within the target value. The optimum combination of the independent parameters was
selected based on the desirability values. Graphical optimization was also perfomed to
determined the optimum experimental conditions to obtain the target values for residual
crystallinity and drug degradation. An overlay plot was constructed to determine design
space of the independent parameters. Within the design space, any combination of the
independent parameters results in a target residual crystallinity of less than 15% and a
drug degradation of less than 5%.

3.8.9. Validation of the Experimental Design
The experimental design was validated using the linear correlation plots, the
residual plots and the values of bias. The experimental design was validated to quantify
the agreement between the predicted values and the experimentally determined values.
Six different drug-polymer dispersions were prepared at various drug loadings, heating
rate and processing temperature using DSC. The residual crystallinity and drug
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degradation of the six drug-polymer dispersions were experimentally determined. The
predicted values from the experimental design were compared with the experimentally
determined values using linear correlation plots and residual plots. The mean percentage
prediction error (percentage bias) was also calculated to determine the ability of the
experimental model to predict the response variables. A lower value of percentage bias
indicates that the model is not biased and can effectively predict the response variables.

3.8.10. Preparation of Drug-Polymer Dispersions Using Hot Melt Extrusion
Hot Melt extrusion was carried out using an 11-mm parallel twin screw melt
extruder (Process 11, Thermo Fisher Scientific, Waltham, MA) comprising of 8 electric
heating zones with an L/D ratio of 40. The feed zone (Zone 1) was maintained at room
temperature and the subsequent zones (Zone 2, Zone 3, Zone 4, Zone 5, Zone 6 and Zone
7) were setup at increasing temperature gradient as shown in Figure 2. Two high
kneading elements (at zone 3 and between zone 6 and 7) and one low kneading element
(between zone 4 and 5) were used. An extrusion element was used at the end of the barrel
for the formation of extrudates (65). The screw speed was varied between 50 and 150
rpm and the maximum temperature of the heating zones was set at 150 °C. The extrudates
were collected and cooled down until further analysis.
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Figure 4: Screw design for HME used for processing MFA-EPO powder blends. K1, K2
and K3 represent the kneading elements.
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3.8.11. Preparation of Drug-Polymer Dispersions Using Vacuum Compression
Molding
A novel vacuum compression molding (VCM) tool was used to prepare the drugpolymer dispersions and compare them with HME filaments. The VCM tool has a
cylindrical design and consists of a main body, a base plate, a lid, a piston and separation
foils. The lid and the base plate have O-ring seals that provide a gas-tight closure when
connected to the main body (66). Since the particle size difference between the drug and
the polymer was high, the sample was prepared by dissolving the drug and the polymer in
acetone prior to sample preparation. The solvent was evaporated until a molten mixture
was observed. This molten mixture was then enclosed between two Teflon foils and
loaded into the sample chamber. The tool was then placed on a pre-heated hot plate at
150 °C. The heat was transferred across the base plate to the sample forming a
homogeneous bubble-free specimen. The samples were heated for a total of three
minutes then the tool was subsequently cooled down and disassembled. The samples
obtained were stored in an airtight container until further analysis.

3.8.12. Characterization of Drug-Polymer Dispersions Prepared Using HME and
VCM
The drug-polymer dispersions prepared using HME and VCM were characterized
to determine the total degradation and residual crystallinity of MFA according to the
procedure mentioned earlier. Additionally, solid state characterization of the samples was
performed using pXRD and DSC analysis to determine the crystalline state of MFA and
the glass transition temperature (Tg) of the drug-polymer dispersions, respectively.
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Figure 5: Parts of Vaccum compression molding (VCM) tool used to prepare drugpolymer samples
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3.9. Estimation of Physical Stability of ASDs Using Modified Avarami Equation
3.9.1. Preparation of MFA Seed Crystals
Seed crystals of MFA were prepared by dissolving 1 g MFA in 40 ml of acetone
using a sonicating water bath (Elmasonic S 50R, USA). After the drug was completely
dissolved in the acetonic solution, the sonicator was turned off and samples were left in
the water bath overnight for slow cooling. The crystals were collected after all the solvent
was evaporated and stored until further analysis.

3.9.2. Preparation of Drug-Polymer Dispersions Using Heat Molding
The ASDs of MFA-EPO were prepared using a heat molding system developed
in-house. The drug and the polymer were size reduced in a mortar and pestle and then
sieved using #270 sieve (53 µm opening). Approximately, 2 g of MFA-EPO mixture
(4:6) was prepared by properly weighing on a weighing balance and then transferred on
to a hot plate. A 2 cm diameter cylindrical mold was placed on the hot plate and the drugpolymer mixture was placed in between two PTFE films. The drug-polymer mixture was
evenly distributed inside the mold using a 2 cm die and the mixture was heated until 160
°C for 15 min. The samples were carefully transferred into a cooling chamber and flash
cooled using nitrogen gas. After the samples were cooled, they were milled in a
cryogenic mill to obtain a fine powder. The samples were taken out and stored at room
temperature until further analysis.
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3.9.3. Modified Avarami Equation to Estimate the Physical Stability of ASDs
The modified Avarami equation contains of two essential assumptions – (i)
nucleation rate is proportional to amorphous fraction, and (ii) crystal size grows linearly
with respect to crystallization time from t = 0 to the final crystal size. These assumptions
can be mathematically expressed as:
() =  (1 − ())

(22)

where Jo is the initial nucleation rate and 1- α(t) is a function of crystallization time.
 = 

(23)

where r is the radius for spherical crystal, and β is crystal growth rate. During the time
interval τ to dτ, the number of nuclei generated is:
 =  1 − ()

(24)

Since each nuclei will grow into a sphere of radius β(t-τ ), the increased volume due to
nuclei appearing in the time interval will be:
() =




  ( − )  1 − ()

(25)

where V(t) is the volume transformed into the crystalline state. It is also related to the
relative crystallinity by the Avrami phase transition theory:
1 − () = (())

(26)

The derivative of the above equation provides an expression for the created crystalline
volume in differential form:
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() =



()

()

(27)

A relationship between (t) and  is established by solving Eqs. (25) and (27):

()
()

=




   ( − ) 

(28)

Integration of eq. (28) gives the final model equation for spherical crystal growth:
α(t) = 1 −



(29)



where k is crystallization rate constant, expressed as the production of nucleation rate
constant, Jo, and crystal growth rate constant, β.


 =   


(30)

A more general form for relative crystallinity can be presented as:


α(t) = 1 − 

(31)

Where the exponent, n, describes the dimensionality of crystal growth, and equals
2, 3 and 4 for rod, plate, and spherical geometry, respectively for homogeneous
nucleation. A general form of k can be expressed in terms of activation energy, ΔEA, and
T according to the Arrhenius equation (Eq. 32). (Yoshioka et al., 1994):
 =  exp −

∆




(32)

Where ko is the pre-exponential factor, R is the universal gas constant, and T is the
absolute temperature in the unit of kelvin. By correlating the crystallization rate constant,
k, as a function of relative humidity and temperature, the optimum stability conditions of
amorphous solid dispersions can be determined.
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3.9.4. Preparation of Stability Chambers Using Saturated Salt Solutions
The drug-polymer samples were stored at various relative humidity (% RH) and
temperatures as shown in Table 3. The ASD samples were stored in glass humidity
chambers with different saturated salt solutions. The humidity chambers were kept in
laboratory oven (VWR International, USA) at different temperatures. The relative
humidity and temperature of the humidity chambers were monitored using
humidity/temperature monitor (Sper Scientific, China).
3.9.5. Determination of Relative Degree of Crystallinity
The ASD samples stored at various storage conditions were taken out periodically
at predetermined time points, and the extent of recrystallization was determined using a
DSC by heating the samples from 30 °C to 240 °C at 20 °C/min. The relative degree of
crystallinity, α(t), was calculated using the following equation (Eq. 33):
α(t) =

∆()
∆

(33)

Where ∆() is the heat of fusion of the drug at a time, t, and ∆ is the heat of fusion of
the drug after complete recrystallization.
3.9.6. Estimation of Recrystallization Rate Constant, k
The recrystallization rate constant, k, was estimated using the mathematical model
according to eq. (33). A non-linear regression analysis was performed between the
relative degree of crystallinity, α(t), with respect to time, t, using Origin Pro V.8.5
(Massachusetts, USA). The dimensionality of crystal growth, n, was set as n = 2 and n >
0.
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Table 3: Various storage conditions used to study the recrystallization kinetics of drug
from the polymeric carrier

Purpose

Saturated Salt
Solution

Relative
Temperature (
Humidity (%)
°C)

Sodium Chloride

25

75

Sodium Chloride

40

75

crystallization rate

Sodium Chloride

60

75

constant, k

Sodium Chloride

80

75

Sodium Chloride

100

75

Lithium chloride

60

11

60

22

60

32

To study the effect of
temperature on the

To study the effect of

crystallization rate

Potassium
Fluoride
Magnesium
chloride

constant, k

Potassium Iodide

60

57

Sodium Chloride

60

75

relative humidity on the
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4. Results and Discussion
4.1. Thermal analysis of Mefenamic acid (MFA) and Polymers
The physicochemical evaluation of the drug (MFA) and the thermoplastic
polymers was conducted using DSC and TGA. The plots of thermogravimetric analysis
of MFA is shown in Figure 6a. The weight loss of MFA when heated between 180 °C
and 230 °C was found to be 4.3%. This indicates that mefenamic acid undergoes
degradation before its melting point. Beyond 230 °C, rapid degradation of MFA was
observed until 270 °C with a total weight loss of 68.5%. This was possibly due to
increased molecular mobility of MFA after melting thereby exposing the carboxylic acid
group (-COOH) of the molecule. The results obtained by thermo-gravimetric analysis are
in accordance with the thermal decomposition of MFA observed by rapid ESI-MS
method as reported by Zhou and Gilpin (67). The authors reported that when MFA was
dissolved in a mobile phase consisting of methanol-water (80:20 v/v) and subjected to
thermal degradation between 130 °C and 230 °C, MFA was converted to MFA-H+, which
is completely converted to the final decomposition fragment with an m/z value of 224 at
a temperature of 230 °C. In the present study, only 4.3% degradation was observed at
230 °C. This was possibly due to the nature of the sample where MFA was present in
solid form rather than molecularly dispersed form. Also, the time scale of thermogravimetric analysis was a magnitude of minutes in the case of rapid ESI-MS, it was
hours which provides sufficient time and energy for degradation of MFA.
The DSC thermogram of MFA showed two endotherms, a shallow endotherm at
170 °C indicating polymorphic change of MFA from form I to form II followed by a
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sharp endotherm at 231 °C indicating melting of form II (Fig. 6b). The melting of MFA
is followed by its degradation due to decarboxylation. The cooling cycle showed an
exothermic peak with a low intensity at 110 °C which indicates that mefenamic acid is
not a glass former and undergoes recrystallization during cooling. An endothermic peak
was observed in the second heating cycle which indicated the melting of the residual
crystalline MFA from the cooling cycle. The results from the thermal analysis
demonstrated the thermal degradation and recrystallization potential of MFA making it a
challenging molecule to process using hot-melt extrusion.
The DSC scans of the polymers is shown in Figure 7. The glass transition
temperature, Tg of the polymers was found to be in between the range of 55 to 101 °C.
The absence of any other thermal event during the scans showed that the polymers were
amorphous.
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Figure 6: (a) TGA thermogram showing degradation of MFA in the temperature range
between 180 °C and 270 °C, (b) DSC thermogram showing recrystallization of
MFA during heat-cool-heat cycle
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Figure 7: DSC curves of polymers showing their glass transition temperature
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4.2. Calculation of Solubility Parameters
4.2.1. Hildebrand and Hansen Solubility Parameters
The values of the solubility parameters of MFA and the polymers estimated
according to Hildebrand and Hansen method have been summarized in Table 4. It was
observed that the values of the solubility parameter of the polymers were very similar
according to both Hildebrand and Hansen method. However, the value of Hildebrand
solubility parameter for MFA was found to be 20.40 MPa0.5 whereas that of Hansen
solubility parameter was 23.59 MPa0.5. The difference between the two values was
mainly due to the fundamental difference between Hildebrand and Hansen methods. In
the Hildebrand method, the solubility parameter was calculated using only the cohesive
energy density of the molecules whereas in Hansen method, the solubility parameter is
dependent on the dispersive, polar and hydrogen bonding forces in a molecule.
Irrespective of the method used, both Hildebrand and Hansen approach demonstrated that
the difference in the solubility parameter between MFA and the polymers was < 7 MPa0.5
that indicates a good miscibility between MFA and the polymers according to
Greenhalgh (68). Upon comparing the values of Hildebrand solubility parameters of
MFA and the polymers, it can be inferred that MFA would have good miscibility with
F68 due to a very small difference in the values of solubility parameters of the two (∆δ =
0.04 MPa0.5). Based on the solubility parameters of MFA and the polymers, it can be
predicted that the order of miscibility of MFA in the four polymers according to the
Hildebrand solubility parameter will be F68> EPO> SLP> VA64. The values of the
Hansen solubility parameter of the drug and the polymers also indicated that MFA would
exhibit the highest miscibility with F68 with the order of its miscibility in the four
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polymers being F68> SLP> VA64> EPO. To further understand the effect of solubility
parameters on drug-polymer miscibility, Bagley plot was constructed using the Hansen
solubility parameters.
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Table 4: Physicochemical properties and the calculated values of Hildebrand and Hansen
solubility parameters of mefenamic acid (MFA) and Eudragit® EPO, Soluplus®,
Kollidon® VA64, and Pluronic® F68
Hildebra
Fdi

F2pi

(J/cc)0.5.

(J/cc)0.5.m

Materi

V
(cc/mo
(J/mol)

mol-1

ol-1

Interaction
parameter, χ

nd

Ehi

al

Hansen
solubilit
solubility

l)

y, δt

Hildebra
nd

Hanse
n

,δ

MFA

4390

220720

13100

185.8

20.40

23.59

-

-

EPO

6010
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4.2.2. Construction of Bagley Plot
The Bagley plot (Fig. 8) represents the three-dimensional solubility parameters
determined using the three intermolecular forces (δd, δp , δh) in a two-dimensional plot
(δv, δh) according to Bagley et al. (62). It was observed from the plot that MFA was close
to EPO indicating good miscibility between MFA and EPO. The distance between the
drug and the polymer in the Bagley plot referred as Ra,v was calculated according to the
following equation:

, = ( −  ) + ( −  )

(34)

According to Bagley et al., when the Ra,v value is <5.6 MPa0.5, the drug and the
polymer are miscible and when the Ra,v values is > 5.6 MPa0.5, it indicates that the drug
and the polymer are immiscible. The Ra,v values were found to be 4.70 MPa0.5, 1.73
MPa0.5, 1.09 MPa0.5 and 1.08 MPa0.5 for MFA-EPO, MFA-SLP, MFA-VA64 and MFAF68, respectively. Based on the Ra,v values, one can therefore conclude that MFA will be
miscible in all the four ploymers. By comparing the values of Hildebrand solubility
parameters and Hansen solubility parameters, and the Bagley plots, it can be seen that
three methods predicted the miscibility of MFA differently in different polymers. The
Hildebrand approach predicted that MFA would have a good miscibility with EPO
whereas the Hansen approach predicted that MFA would have good miscibility with
VA64. The Bagley plots predicted that MFA would have a good miscibility with SLP.
This discrepancy between the three approaches was possibly due to the fundamental
difference in the calculation of the solubility parameters and the methodology used to
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predict the miscibility. While the Hildebrand approach is based on the calculation of the
cohesive energy density of the molecules, the Hansen approach is based on calculating
different intermolecular forces in a molecule. However, it should be noted that all the
theoretical approaches indicated that the drug MFA will be miscible in all the four
polymers. This shows that the assumption that a difference in the solubility parameter,
∆δ, of < 7 MPa0.5 between the drug and the polymer does not always indicate miscibility.
However, since these are theoretical estimates, these results were, therefore, validated
using the melting point depression method which is an experimental approach.
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Figure 8: Bagley plots of hydrogen bonding forces as a function of combined solubility
parameter for mefenamic acid, Eudragit® EPO, Soluplus®, Kollidon® VA64,
and Pluronic® F68
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4.3. Melting Point Depression of Mefenamic acid in Various Polymers
The plots of melting point depression of MFA as a function of polymer fraction in
various polymers are shown in Figure 9 and the numerical data are given in Table 5.
From Figure 9, it can be seen that the melting point of MFA decreased rapidly in the
presence of SLP, followed by EPO, VA64, and F68. The melting endotherm of MFA
was not observed after 60%, 75%, 75% and 50% concentration of MFA-EPO, MFA-SLP,
MFA-VA64 and MFA-F68, respectively. This indicates concentration-dependent
miscibility of MFA with the four polymers. It was interesting to observe that the melting
temperature of MFA changed with the polymer. This was possibly due to difference in
the thermal conductivity and melt viscosity of the polymers. The absence of melting
endotherm in the case of MFA-SLP and MFA-VA64 below 75% MFA may be due to the
presence of MFA in microcrystalline form at the melting temperature. In that case, the
value of heat of fusion, ∆Hf, of these crystals was too low to be detected by DSC.
However, based on the results from melting point depression, it can be concluded that
MFA had concentration-dependent miscibility with both EPO and SLP. To further
understand the miscibility of MFA in the four polymers, mathematical models were used
to estimate the value of drug-polymer interaction parameter, χ, and the mole fraction of
MFA dissolved in the polymer, xdrug.
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Table 5: Depression in the melting point of mefenamic acid (MFA) with increasing
concentration of Eudragit® EPO, Soluplus®, Kollidon® VA64, and Pluronic®
F68

Melting Temperature of Mefenamic acid (ºC)
MFA (%
w/w)

Eudragit® EPO

Soluplus®

Kollidon® VA64

Pluronic® F68

95

230.30±0.46

231.10±0.22

230.68±0.72

230.15±0.95

90

228.64±0.26

229.50±0.21

229.64±0.34

229.95±0.68

85

226.81±0.32

227.11±0.16

228.21±0.51

229.64±1.22

80

224.71±0.85

223.41±0.58

227.28±0.56

229.13±0.94

75

221.98±0.65

218.93±0.42

225.04±0.87

228.57±0.86

70

218.20±0.97

-

-

227.64±0.75

60

208.86±1.32

-

-

225.40±1.06

55

-

-

-

223.87±0.65

50

-

-

-

221.85±1.33

* The data are presented as mean ± standard deviation (n=3).
**The blank spaces in columns indicate that no melting endotherm was observed for
these drug-polymer concentrations.
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Figure 9: Plot showing depression in the melting point of MFA as a function of polymer
fraction (by volume) in the drug-polymer mixture. The error bars represent
mean ± standard deviation (n=3).
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4.4. Estimation of Drug-Polymer Interaction Parameter from Melting Point
Depression Data
The melting point depression of MFA resulting because of polymers may be used
to estimate the value of drug-polymer interaction parameter, χ. In the present
investigations, the relationship between an increase in the polymer concentration in the
drug-polymer mixture resulting in a decrease in the melting point of MFA was plotted
according to eq. (6) (Fig. 10). A linear relationship was observed for all the drugpolymer mixtures which allowed for the estimation of the value of interaction parameter,
χ, from the slope of the fitted line. A negative value of the interaction parameter was
observed for MFA-EPO, MFA-SLP and MFA-VA64 mixtures indicating good drugpolymer miscibility. A positive value of the interaction parameter was observed in MFAF68 mixtures indicating that they were immiscible or poorly miscible. Also, a closer look
at the MFA-EPO plot shows a lack of linearity at higher concentration of MFA (Fig. 10).
This suggests a dependence of the interaction parameter, χ, on the composition of the
MFA-EPO mixture. This observation is in agreement with the previously reported studies
involving mixtures of carbamazepine and Soluplus® (69) and nifedipine and poly(vinyl
pyrrolidone) (70). Also, the value of interaction parameter, χ, for MFA-SLP mixture was
found to be -3.05 which according to Marsac et al. indicates adhesive enthalpic
interaction of favorable miscibility between MFA and SLP (42).
The temperature dependence of the interaction parameter exhibits first-order
kinetic relationship according to eq. (8). The plot of values of interaction parameter, χ, as
a function of 1/T for various drug-polymer mixtures is shown in Figure 11. In the case of
MFA-F68 system, a linear relationship between the values of χ and 1/T was observed
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across the experimental composition of 80% to 50% MFA in the composition with an R2
value of 0.7747. In the case of MFA-EPO system, a linear relationship was observed
from 80% to 60% MFA composition with an R2 value of 0.9703. For the MFA-SLP
system, a linear relationship was observed from 85% MFA to 75% MFA with an R2 value
of 0.9896. Similarly, for the MFA-VA64 system, a linear relationship was observed from
85% to 75% MFA with an R2-value of 0.9859. A non-linear relationship was observed at
lower values of 1/T that corresponds to higher temperature and high drug loading. This is
in line with previously reported studies where non-linearity was observed at high drug
loading in the case of indomethacin-PVP-VA64 system (70) and felodipine-Soluplus®
and felodipine-HPMCAS systems (28). The regression equation from the linear region in
Figure 6 was used to estimate the entropic (A) and enthalpic (B) constants of
corresponding drug-polymer mixtures. These values were used to obtain the value of
interaction parameter at various temperatures which were subsequently used to estimate
the mole fraction of MFA dispersed in the polymeric carrier according to eq. (16).

(1/Tm −1/Tm0 )∗(−∆H/R)− (lnϕdrug+(1−1/m) ϕpoly)
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Figure 10: Estimation of interaction parameter of mefenamic acid in various polymers
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Figure 11: Plot of the value of the drug-polymer interaction parameter, χ, as a function of
temperature.

71

4.5. Estimation of Gibbs Free Energy of Mixing
The Gibbs free energy of mixing, ∆Gmix indicates the energy change (enthalpy)
and the disorderliness (entropy) in a drug-polymer mixture. A negative value of ∆Gmix
indicates miscibility and a positive value indicates immiscibility between drug and the
polymer. Since the drug-polymer mixtures are non-ideal systems, the total Gibbs free
energy of mixing is expressed as ∆Gmix/RT. Estimation of ∆Gmix/RT at various
temperatures helps to determine the critical processing temperature required for complete
mixing of the drug and the polymer. The plot of Gibbs free energy of mixing, ∆Gmix/RT,
as a function of volume fraction of MFA in the four polymers at various temperatures is
shown in Figure 12. It was observed that the interaction parameter significantly affected
the Gibbs free energy of mixing of MFA in all the four polymers. At room temperature
(25 °C), the Gibbs free energy of mixing, ∆Gmix/RT, was positive for all the drugpolymer mixtures, indicating immiscibility. As the temperature increased, the values of
Gibbs free energy of mixing, ∆Gmix/RT, decreased and eventually became negative,
indicating miscibility. In the case of the MFA-VA64 system, the effect of temperature on
the Gibbs free energy of mixing was found to be significant compared to other drugpolymer mixtures.
The temperature at which the Gibbs free energy becomes negative depended on
the polymer. In the case of MFA-F68 and MFA-VA64 system, the Gibbs free energy
was negative at 200 °C, and in the case of MFA-SLP and MFA-EPO, it was at 140 °C.
These temperatures indicate the formation of a homogeneous mixture that was
thermodynamically stable at all drug-polymer compositions. The information from these
plots is helpful in setting up the processing conditions in hot-melt extrusion.
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Figure 12: Plots of the values of Gibbs free energy, ∆Gmix/RT, versus volume fraction of
the drug, ϕdrug, for drug-polymer mixtures at 25 °C, 100 °C, 140 °C, 200 °C,
and 240 °C
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4.6. Validation of Gibbs Free Energy Plots
The polarized light microscopy images of MFA in various polymers at different
temperatures are shown in Figure 13. The morphology of the MFA crystals at 50 °C was
distinct in different polymers. While sharp needle like crystals were observed in case of
MFA-VA64 (Fig. 13(j)), small rod like crystals were observed in case of MFA-F68 (Fig.
13(d)). In the case of MFA-EPO and MFA-SLP, the drug crystals were present as small
aggregates along with the polymer (Figs. 13a and 13g). The morphology of the crystals at
room temperature itself indicated that MFA had good miscibility with EPO and SLP. The
onset temperature is the point where the MFA crystals just start to melt and dissolve in
the polymeric matrix. In case of MFA-EPO system, the onset temperature was observed
at around 130 °C (Fig. 13)) and almost all the MFA crystals were dissolved in EPO by
150 °C (Fig. 13c). These results were in accordance with the Gibbs free energy plots
which predicted that the upper solution critical temperature (USCT) of MFA in EPO in
between 100 - 140 °C. Similarly, the USCT of MFA-F68 and MFA-VA64 were found to
be in between 180 °C - 200 °C (Figs. 13f and 13l)) and for MFA-SLP it was found to be
in between 130 °C - 150 °C (Fig. 13i). These results were in accordance with the
predicted values of the Gibbs energy plots (Fig. 12) which establishes the validity
between the theoretically predicted and the experimentally observed values. These values
can be further used in establishing the processing temperatures for hot melt extrusion.
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Figure 13: Polarized light micrographs of 1:1 ratio of MFA-EPO at 50 °C (a), 130 °C (b),
and 150 °C (C); MFA-F68 at 50 °C (d), 180 °C (e), and 200 °C (f); MFA-SLP
at 50 °C (g), 130 °C (h), and 150 °C (i); and MFA-VA64 at 50 °C (j), 180 °C
(k), and 200 °C (l)
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4.7. Determination of Solubility, Miscibility and Glass Transition Curves
A typical thermodynamic phase diagram consists of a solubility curve, a
miscibility curve and a glass transition curve. Initially, the activity coefficient, γdrug of
MFA in the polymers was estimated using Hansen solubility parameter. Later, these
values were used to estimate the value of xdrug which is mole fraction of molecularly
dispersed drug in the polymer using solid-liquid equilibrium (SLE) equation. This
information was used to construct the solubility curve according to F-H lattice theory.

4.7.1. Estimation of Activity Coefficient of Mefenamic acid in Various Polymers
The value of activity coefficient of MFA in various polymers was calculated
using to eq. (12) for various drug-polymer mixtures with MFA concentration in the
mixture ranging from 2.5% w/w to 50% w/w. Figure 14 shows plots of temperature
dependence of the values of activity coefficient, γdrug, for various drug-polymer mixtures.
The drug-polymer miscibility is expected to increase with an increase in the temperature
due to an increase in the mobility of the drug and the polymeric molecules. The dotted
lines in the plots shown in Figure 14 indicate the ideal mixing in which case the value of
activity coefficient is 1 (i.e., lnγdrug = 0). From the plots, it can be observed that the
activity coefficient of MFA was dependent on the ratio of MFA in the drug-polymer
mixture for all the four drug-polymer mixtures. An increase in the concentration of MFA
in the mixture resulted in an increase in the value of activity coefficient of the drug, γdrug.
However, for all the drug-polymer mixtures, the value of activity coefficient was found to
be <1 (i.e., lnγdrug < 0) for up to 25% w/w MFA at room temperature (25 °C). Frank et al.
have reported that a solid solution is formed when the value of the activity coefficient,
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γdrug <1 (71). According to this, MFA should form a solid solution with all the four
polymers at room temperature at a drug loading of 25% w/w and lower. However, in the
present study, this was not the case as the results of the melting point depression showed
that MFA was immiscible in all the four polymers at a drug loading of 25% at room
temperature. This clearly shows that the value of the activity coefficient of MFA in the
four polymers was underestimated due to its mathematical form. In eq. (12), it can be
clearly seen that the difference in the magnitude of dispersion, hydrogen bonding and
polar forces between the drug and the polymer determine the value of the activity
coefficient. However, it does not consider the fact that even when the difference in the
magnitude is lower for one of the three forces, the drug and polymer will be miscible in
each other. While estimation of the value of activity coefficient using eq. (12) include
contribution of all types of intermolecular forces equally which resulted in the values of
activity coefficient of MFA obtained with the four polymers to be relatively low that
resulted in overestimation of drug-polymer miscibility.
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Figure 14:Plots demonstrating the change in the value of activity coefficient, γdrug, of
MFA as a function of temperature. The figure legends indicate % weight
fraction of the drug (MFA) in the drug-polymer mixture.
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4.7.2. Estimation of Mole Fraction Solubility of Mefenamic acid in Various
Polymers
The mole fraction of MFA dispersed in the four polymers studied as a function of
temperature was estimated according to eq. (10) and the results are plotted in Figure 15.
The horizontal dotted line in the plots indicates the ideal case of complete dissolution of
MFA in the polymers. It can be observed from the plots that the mole fraction solubility
of MFA in all the polymers was composition-dependent at room temperature whereas it
was found to be independent of drug composition (up to 5% w/w) at higher temperatures.
In the case of the MFA-SLP mixture, the complete dissolution of MFA in SLP was
observed at ~125 °C. In the case of MFA-EPO, it was observed at ~150 °C, for MFAF68 it was observed at ~200 °C, and for MFA-VA64 it was observed at ~205 °C. The
temperature at which the mole fraction of MFA dispersed in the polymers was less than 0
(xdrug = 0) is termed as the critical temperature (Tc). At this critical temperature, MFA
starts to disperse in the polymer. For MFA-SLP and MFA-EPO system, the critical
temperature was found to be dependent on the composition of MFA in the mixture
whereas in the case of MFA-F68 and MFA-VA64, it was found to be independent of the
composition. The critical temperature was found to be in between 85-95 °C for MFASLP, 90-110 °C for MFA-EPO, 175-185 °C for MFA-F68, and 195-200 °C for MFAVA64. This information will be helpful to fix the processing conditions during hot-melt
extrusion.

79

Figure 15: Plots demonstrating the change in the mole fraction of dispersed MFA as a
function of temperature estimated using Flory-Huggins theory. The figure
legends indicate % weight fraction of the drug (MFA) in the drug-polymer
mixture.
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Another approach to estimate the mole fraction of MFA dispersed in the polymeric
carrier is by use of solid-liquid equilibrium (SLE) equation. According to eq. (11), the
mole fraction of MFA dispersed in the polymers was estimated using the values of the
activity coefficient of MFA in the polymers obtained using eq. (12). The mole fraction,
xdrug, of MFA dispersed in the polymers as a function of temperature is presented in
Figure 16. The results demonstrated that the mole fraction of MFA dispersed in the
polymer increased as a function of temperature, however, an increase in the concentration
of MFA in drug-polymer mixture led to the decrease in the miscibility of MFA in the
polymer. At lower temperatures (i.e., < 75 °C), the drug-polymer miscibility was found
to be independent of drug-polymer composition, however, at higher temperatures, the
miscibility was composition-dependent and decreased with an increase in the
concentration of MFA in the mixture. Ideal mixing was observed for up to 5% w/w
concentration of MFA in the mixture which indicates complete molecular dispersion of
MFA in all the four polymers. Unlike the results obtained from Flory-Huggins theory, no
negative values were obtained for xdrug using the solid-liquid equilibrium (SLE) equation.
A closer look at the plots in Figure 16 shows that the mole fraction, xdrug, of MFA
dispersed in the polymers is both dependent on temperature and drug loading, making it
difficult to determine the solubility curve using the theoretical approach. Therefore, a
simple and novel approach was used in the current study to determine the solubility of
MFA in the polymers.
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Figure 16: Plots demonstrating the change in the mole fraction of dispersed MFA as a
function of temperature estimated using the solid-liquid equilibrium (SLE)
equation. The figure legends indicate % weight fraction of the drug (MFA) in
the drug-polymer mixture.
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4.7.3. Determination of Solubility Curve Using Melting Point Depression Data
A melting point is the temperature at which the drug crystal overcomes the lattice
energy and gets dissolved in the polymeric matrix. While it is easy to determine the
melting point of MFA in drug-polymer blends with higher drug loading, it is challenging
to estimate the melting point of MFA at lower drug loading. However, it was indirectly
estimated using the melting point depression data. A relationship was established
between the weight fraction of the drug and melting temperature using a polynomial
equation. This relationship was used to estimate the melting temperature of the drug at
lower drug loadings. The plots between the melting temperature and weight fraction of
MFA in various polymers is shown in Figure 17. In all the drug-polymer blends, the
melting point data fitted well with the weight fraction of MFA using a polynomial
equation with R2 values of > 0.99. Based on the polynomial equation, the melting point
of MFA at various drug loadings was determined and this data was used to estimate the
solubility curve.

4.7.4. Determination of Miscibility Curve and Glass Transition Curve
A miscibility curve represents the boundary above which the drug is present at a
supersaturated state and undergoes spontaneous phase separation. Unlike solubility curve,
there are no reported experimental techniques in the literature to estimate the miscibility
of drug and polymer with respect to drug loading and temperature. Therefore, in the
current study, miscibility of MFA in the polymers was estimated according to eq. (16)
using the enthalpic and entropic constants obtained from the melting point depression
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data. The glass transition curve was plotted according to the Gordan Taylor equation
using the glass transition temperature of MFA and the polymers.
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Figure 17: The plots showing a polynomial relationship between the melting temperature
and the weight fraction of MFA in various polymers
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4.7.5. Construction of Thermodynamic Phase Diagrams
The thermodynamic phase diagrams of MFA in the four polymers are shown in
Figure 18. The solubility curve represents the boundary where the fraction of MFA is
dissolved into the polymeric matrix. A miscibility curve represents the boundary above
which the drug is present at a supersaturated state and undergoes spontaneous phase
separation. The glass transition curve, Tg predicted using the Gordan-Taylor equation
indicates the molecular mobility of the drug and the polymer within the amorphous solid
dispersion system. In the region above the Tg curve, phase separation is
thermodynamically favored due to increase in the mobility of the polymeric strands,
which reduces the activation energy for nucleation and subsequently, crystal growth.
Below the Tg curve, the system remains stable due to the kinetic hinderance caused by the
polymeric strands. The region between the miscibility curve and the solubility curve
indicate the metastable zone where the drug-polymer system remains stable at
temperatures below Tg but can undergo phase separation at temperatures above Tg. The
point where the miscibility curve intercepts the glass transition curve is called Berghmans
point (72). It theoretically defines the maximum drug concentration that will be stable
without undergoing phase separation until the temperature reaches the Tg of the drugpolymer mixture. By comparing the thermodynamic phase diagrams of MFA in the four
polymers, the miscibility of MFA is higher in case of EPO, followed by SLP, F68 and
VA64. The Berghmans point was found to be around 13% w/w of MFA in both MFAEPO and MFA-SLP systems. However, the metastable zone is narrow in case of MFASLP system, indicating that a small fluctuation in the formulation can lead to phase
separation.
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Figure 18: Thermodynamic phase diagrams of MFA in the four polymers showing the
solubility curve, miscibility curve, and the glass transition curve. The arrows
represent the Berghmans point of MFA in each polymer.
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4.8. Process Optimization of HME Using Material Sparing DSC Method
The critical elements in preparing ASDs using HME are the drug loading,
temperature of the heating zones, the screw design, the screw speed (residence time) and
the feeding rate of the input material. If the processing temperature is high, it can result in
degradation of certain drugs which is detrimental if the degradant is toxic. If the
processing temperature is low, insufficient heat energy is available for the crystalline
drug to convert into amorphous form, resulting in residual crystallinity. Therefore, it is
important to optimize the processing conditions so that minimum drug degradation and
minimum residual crystallinity is present in the ASDs. This can be done by understanding
the interdependency of drug load, processing temperature and the HME screw speed on
the residual crystallinity and drug degradation. However, it requires a lot of experiments
and large amounts of drug to run these experiments. Therefore, there is a need to develop
a material sparing method to determine the ideal processing conditions for HME, with
minimum number of experiments. One such approach could be the use of differential
scanning calorimeter (DSC), which is a commonly used analytical technique. Like HME,
the thermal energy applied while heating the sample in a DSC breaks the crystal lattice of
the drug then the drug becomes miscible in the polymeric matrix depending on its affinity
with the polymer. Therefore, DSC has a potential to be a miniature, material sparing,
screening tool to determine the optimum processing conditions in the preparation of
ASDs using HME. The objective of the following work was to optimize the processing
conditions of HME using DSC and response surface methodology. For this purpose, the
effect of drug loading, heating rate and temperature on the residual crystallinity and
degradation of MFA in EPO was studied using DSC. Initial screening was performed
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using film casting method, hot-stage microscopy and TGA to determine the range of
experimental conditions. Based on this information, a Box-Behnken experimental design
was used to create a total of fifteen experimental runs with an ability to understand the
main effect and the interaction effect between the independent parameters; drug loading
(X1), heating rate (X2) and temperature (X3), and the dependent variables residual
crystallinity (Y1) and drug degradation (Y2).

4.8.1. Results of Initial Screening Experiments to Setup the Experimental Design
The initial screening was performed to determine the ideal conditions for the
experimental design. The polarized light microscope images of various films prepared
using the film casting method is shown in Figure 19. It was observed that at drug loading
of less than 40% w/w drug loading (Fig. 19a) a homogeneous film with very traces of
MFA crystals were observed. At 45% w/w drug loading (Fig. 19b), small amounts of
MFA crystals were observed, indicating recrystallization. In case of 50% w/w drug
loading (Fig. 19c), large drug rich regions were observed on the film indicating that MFA
recrystallized from the polymeric matrix of EPO. Based on the results from film casting
experiments, it could be concluded that a maximum of 40% w/w MFA was miscible with
EPO without undergoing recrystallization at room temperature. Alshehri et al. reported
that a maximum of 25% MFA was miscible with EPO when processed using HME (73).
In another study, Kojima et al. reported that a maximum of 24% MFA was miscible with
EPO when processed using cryo-milling (74). The higher drug loading achieved in the
case of film casting can be attributed to its high mixing efficiency as compared to HME
or cryo-milling. In the case of film casting, the drug and polymer are molecularly
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dispersed in a common solvent resulting in higher mixing efficiency. In the case of HME
and cryo-milling, the mixing efficiency was much lower resulting in drug-polymer
dispersions with regions having higher drug concentration. These drug rich regions
initiate nucleation, followed by crystal growth and recrystallization of drug. Therefore, it
is safe to assume that the maximum drug loading achieved using HME or cryo-milling is
always lower than the film casting method. Hence, 40% w/w drug loading was taken as
the higher level of drug loading in the experimental design. The lower level of drug
loading was taken as 20% w/w based on the published literature and to ensure that a wide
range of responses were observed from the experimental design. Based on the results of
film casting method, the powder blend containing 40% w/w drug loading was prepared in
a mortar and pestle and analyzed under hot stage microscopy. Figure 19 shows the hot
stage microscopy images of 40% drug loading at various temperatures. It was observed
that at around 60 °C (Fig. 19d), EPO started to transform into rubbery state. At around
100 °C (Fig. 19e), EPO completely transformed into a rubbery state exposing the MFA
crystals. At around 140 °C (Fig. 19f), a homogeneous mixture was observed indicating
that MFA crystals dissolved into the polymeric matrix of EPO. Although MFA has a high
melting point of 231° C, it was miscible in EPO at much lower temperature due to a
phenomenon called melting point depression. Once the EPO molecules undergo glass
transition, the higher mobility of EPO molecules reduces the chemical potential of MFA
crystals, thereby reducing the total energy required to break the crystal lattice. This
results in the melting of MFA at much lower temperatures than its melting point (75).
The results of the hot stage microscopy (HSM) suggest that the minimum temperature at
which MFA and EPO are miscible with each other (at 40% w/w drug loading) is around
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140 °C. Therefore, it was taken as the lower level for temperature (X3) in the
experimental design.
The higher level for the temperature and the experimental level for heating rate
were determined using TGA analysis. Initially, the % weight loss of pure EPO was
determined for upto 250 °C to ensure that the polymer was stable at such high
temperature. It was observed that less than 2% of EPO degraded at around 250 °C, which
showed that EPO was stable at ahigh temperature. The powder blends containing 40%
w/w MFA-EPO were analyzed using TGA at various heating rates. Based on the TGA
data, it was observed that the rate of degradation of MFA was dependent on the heating
rate of the TGA. Since EPO was proved to be stable at a high temperature, any weight
loss observed during the TGA analysis could be attributed to the degradation of MFA. It
was evident from the data that most of the MFA underwent degradation at around 220
°C. Therefore, the higher level for the heating temperature (X3) was taken as 220 °C in
the experimental design. The relationship between the TGA heating rate and the %
weight loss of MFA at 220 °C is shown in Figure 20. It was observed that at heating rates
of 0.1 °C/min to 1 °C/min, the % weight loss of MFA was more than 60%. As the heating
rate increased from 1 °C/min to 10 °C/min, the % weight loss decreased exponentially.
At higher heating rates of 10 °C/min to 20 °C/min, the % weight loss remained low at
around 10%. Since a significant amount of weight loss took place between 1 °C/min to
10 °C/min, these values were taken as the lower lever and higher level for the heating rate
(X2), respectively, in the experimental design.
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Figure 19: Polarized light microscopy images of films prepared by film casting method:
40% w/w drug loading (a), 45% w/w drug loading (b), 50% w/w drug loading
(c). Hot stage microscopy images of 40% w/w MFA-EPO powder blends at 60
°C (d), 100 °C (e) and 140 °C (f).
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Figure 20: Relationship between % weight loss (drug degradation) at 220 °C and heating
rate analyzed using TGA
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4.8.2. Box-Behnken Design and Observed Responses
The fifteen experimental runs along with the observed responses are given in
Table 6. Within the studied experimental domain, the minimum value of residual
crystallinity (Y1) was found to be 1.0 ± 0.3% and the maximum value was found to be
33.5 ± 4.1%. A minimum % drug degradation (Y2) was found to be 3.5 ± 0.7% and the
maximum value was found to be 26.8 ± 4.2%. Based on the obtained experimental data,
it was difficult to determine the effect of each independent parameters on the dependent
parameters. Therefore, the observed responses were fitted into various models (linear,
cubic and quadratic) to obtain the best fit. It was found that all the responses were fitted
into a second-order quadratic polynomial model. The model coefficients that were not
significant were eliminated and the significant coefficients including the interaction terms
were defined according to the following quadratic equations (Eqs. 35 and 36):

Residual crystallinity (Y ) = 15.57 + 8.61X + 3.28X − 8.34X  + 2.48X X − 1.16X X −

3.93X X + 0.34X − 2.79X + 0.19X 

(Eq. 35)

Drug degradation (Y ) = 8.67 + 2.01X − 3.89X + 7.60X − 0.005X X + 2.68X X −

1.22X X − 0.56X + 2.54X + 2.72X 

(Eq. 36)
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Table 6: Box-Behnken experimental design showing the fifteen experimental runs and
the observed responses
Run

Drug Load

Heating rate

Temperature Residual
Crystallinity
( °C)
(%)

Drug
Degradation
(%)

(%)

( °C/min)

1

30

5.5

180

16.3 ± 2.3

8.5 ± 2.1

2

30

5.5

180

14.9 ± 1.8

7.1 ± 1.4

3

40

5.5

140

33.5 ± 4.1

3.7 ± 0.4

4

30

1

220

5.7 ± 0.9

26.8 ± 4.2

5

30

10

140

28.1 ± 4.8

3.5 ± 0.7

6

30

1

140

14.3 ± 2.2

8.4 ± 2.3

7

40

5.5

220

14.3 ± 5.1

23.5 ± 4.2

8

30

5.5

180

15.5 ± 2.2

10.4 ± 1.5

9

40

1

180

16.5 ± 3.1

16.0 ± 2.8

10

20

10

180

4.8 ± 1.2

5.3 ± 1.8

11

20

5.5

140

15.6 ± 3.3

3.5 ± 1.3

12

40

10

180

28.6 ± 4.5

7.8 ± 2.2

13

20

1

180

2.6 ± 0.4

13.5 ± 4.2

14

20

5.5

220

1.0 ± 0.3

12.6 ± 3.8

15

30

10

220

3.8 ± 0.7

17.0 ± 2.2

All the experiments were performed in triplicate and the results are expressed as
mean±SD (n=3).
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The summary of ANOVA results is shown in Tables 7 and 8. It was found that the
model was significant for all the studied responses. The lack of fit was found to be not
significant which shows that the experimental results had excellent goodness of fit. Based
on the experimental coefficients (Eqs. 35 and 36), it can be observed that drug load (X1)
had a significant positive effect and temperature (X3) had a significant negative effect on
residual crystallinity (Y1). It means, an increase in drug load (X1) results in increase in
residual crystallinity (Y1) while increase in temperature (X3) results in decrease in
residual crystallinity (Y1). Also, the combination of heating rate and temperature (X2X3)
was found to have a negative effect on residual crystallinity (Y1). In the case of %
degradation, temperature (X3) was found to have a positive effect and the heating rate
(X2) was found to have a negative effect. It indicates that an increase in the temperature
and decrease in the heating rate increased the % drug degradation (Y2). To exhibit the
effect of independent factors on the dependent factors, response surface plots and contour
plots were plotted using the observed responses.
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Table 7: Summary of results from ANOVA showing the residual sum of squares, F
statistics and the lack of fit test results

Parameters

SS

DF

MS

F value P Value

Significance

significant

Residual crystallinity (%)
Model

1356.42

9

150.71

105.88

<0.0001

Residual

7.12

5

1.42

-

-

Lack of fit

6.13

3

2.04

4.14

0.2006

Pure error

0.9867

2

0.4933

-

-

Total

1363.54

14

-

-

-

not significant

Drug degradation (%)
Model

700.98

9

77.89

33.57

0.0006

Residual

11.60

5

2.32

-

-

Lack of fit

6.12

3

2.04

0.7431

0.6137

Pure error

5.49

2

2.74

-

-

Total

712.58

14

-

-

-

significant

not significant
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Table 8: Statistical analysis of the observed responses showing the best-fit model,
regression coefficient and coefficient of variation (% CV)

Responses

Model

R2

Adj R2

Pred R2 SD

Quadratic

0.9948

0.9854

0.9264

1.19

8.30

Quadratic

0.9837

0.9544

0.8454

1.52

13.60

% CV

% Residual
crystallinity (Y1)
% Drug
degradation (Y2)
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4.8.3. Response Surface Plots and Contour Plots
Response surface plots exhibit presence of cause and effect relationship among
the studied factors for providing enhanced product and process understanding. The
contour plots and response surface plots indicating the effect of the independent
parameters on the residual crystallinity (Y1) are shown in Figures 21 and 22.

4.8.4. Effect of Independent Parameters on Residual Crystallinity
The contour plot representing the effect of the final heating temperature of the
DSC and the heating rate on the residual crystallinity is shown in Figure 21a. It can be
observed that higher heating rate and lower temperature, increased the % residual
crystallinity. When the heating rate is high, the total time and energy provided to the
sample will be low. As a result, not enough energy is available to break the crystal lattice
of the drug thereby resulting in higher % residual crystallinity. Interestingly, the 3D
response surface plot (Fig. 21b) shows that at lower heating rate, the temperature did not
have any effect on the % residual crystallinity. However, at higher heating rates, the %
residual crystallinity decreased linearly with an increase in the temperature. The contour
plot representing the effect of the temperature and the drug load on the residual
crystallinity is shown in Figure 21c. It was observed that high residual crystallinity was
obtained when the drug load was high, and the temperature was low. On the other hand,
lower values of residual crystallinity were observed at low drug load and high
temperature. When the drug load is high, higher amount of heat energy is required to
break the crystal lattice of MFA. To provide such amount of heat, the MFA-EPO
dispersions should be heated to higher temperature. When enough heat energy is not
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provided, the MFA particles remain in the crystalline form resulting in higher % residual
crystallinity. This shows the importance of the processing parameters on the residual
crystallinity (76). The 3D response surface plot (Fig. 21d) shows that at low
temperatures, the % residual crystallinity increased linearly with an increase in the drug
loading. This shows that when an increase in the processing temperature is a limitation
for HME processing, then the drug load should be decreased to lower the residual
crystallinity. The contour plot representing the effect of the heating rate and the drug
load on the residual crystallinity is shown in Figure 21e. At high drug load and high
heating rate, high residual crystallinity was observed. The 3D response surface plot (Fig.
21f) shows that at low heating rate, the drug load did not show any significant increase in
the residual crystallinity. However, at high heating rate, the drug load significantly
increased the residual crystallinity. This is due to the lower amount of heat energy
provided when the heating rate is high resulting in higher residual crystallinity.
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Figure 21: 2D-contour plots and 3D response surface plots showing the effect of
independent parameters on the residual crystallinity (%)
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4.8.5. Effect of Independent Parameters on Drug Degradation
The contour plot representing the effect of the temperature and the heating rate on
the drug degradation is shown in Figure 22a. It was observed that at lower heating rate
and high temperature, the drug degradation was high. This was due to the excess thermal
energy provided to the drug-polymer dispersions which resulted in breakage of the crystal
lattice of MFA and an increase in the molecular mobility. This exposed the carboxylic
acid group (-COOH) of the molecule which underwent decarboxylation. The results
were in accordance with the thermal decomposition of MFA observed by rapid ESI-MS
method as reported by Zhou and Gilpin (67). The authors reported that when MFA was
dissolved in a mobile phase consisting of methanol-water (80:20 v/v) and subjected to
thermal degradation between 130 °C and 230 °C, MFA was converted to MFA-H+ which
was completely converted to the final decomposition fragment with an m/z value of 224
at a temperature of 230 °C. The 3D response surface plot (Fig. 22b) shows that at lower
heating rate, the temperature has a significant effect on the drug degradation. On the other
hand, at low temperatures, the % degradation remained constant with increase in the
heating rate. The contour plot presenting the effect of the temperature and the drug load
on the degradation is shown in Figure 22c. It was observed that high drug degradation
was obtained when the drug load and the temperature were high. The 3D response
surface plot (Fig. 22d) shows that at low temperature, the drug degradation was low and
remained constant with an increase in the drug load. However, at high drug load, the
degradation increased significantly with an increase in the temperature. The contour plot
representing the effect of the heating rate and the drug load on the drug degradation is
shown in Figure 22e. At high drug load and low heating rates, high drug degradation was
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observed. The 3D response surface plot (Fig. 22f) also show that high drug load and low
heating rate resulted in high drug degradation. However, at lower drug load, the drug
degradation was low and did not change with an increase in the heating rate. Based on the
response surface plots and the contour plots, it is evident that all the three independent
parameters had significant effect on the two studied dependent parameters.
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Figure 22: 2D-contour plots and RSA plots showing the effect of experimental variables
on drug degradation (%)
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4.8.6. Establishment of Design Space
The selection of the optimum formulation was carried out using the numerical and
the graphical optimizations. Initially, the target values for residual crystallinity and drug
degradation were assigned and the numerical optimization was performed to determine
the possible solutions and the desirability values. The optimized batch was selected from
among the solutions obtained for the criteria, i.e. maximu drug load, minimum % residual
crystallinity, and minimum % drug degradation. The solutions with desirability close to
one was considered as the optimum formulation. The results of the numerical
optimization are shown in Table 9.
The optimum processing conditions were also selected using an overlay plot using
the same constraints as that of numerical optimization. Figure 23 shows the overlay plot
between the processing parameters with the design space indicated in yellow shade. The
contour lines indicate the boundary lines set for each of the responses. According to the
overlay plot, it was found that when powder blend containing 20% w/w drug load was
heated at a rate of 5.5 °C/min to the heating temperature of 146 °C, the resulting drugpolymer dispersion contained residual crystallinity of 13.6% with drug degradation of
3.8%. Once the optimum processing conditions was determined, the experimental design
was validated by preparing six checkpoint formulations. The experimentally observed
values of the six checkpoint formulations were compared with the predicted values from
the experimental design.
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Table 9: Results of the numerical optimization performed using desirability
function. The value of desirability close to 1 was selected.

No
.

1

2

3

4

5

6

7

8

9
10
11

Drug

Heatin

loadin

g

g

rate

1.00
0
1.00
0
1.00
0
1.00
0
1.00
0
1.00
0
1.00
0
1.00
0
1.00
0
0.14
7
0.34
8

Processin
g
temperatu
re

Residual

Drug

crystallini

degradati

ty (%)

on (%)

Desirabili
ty

0.000

-0.858

13.605

3.867

0.698

0.000

-0.850

13.541

3.869

0.698

0.000

-0.832

13.408

3.876

0.698

0.000

-0.915

14.030

3.861

0.695

0.000

-0.924

14.100

3.862

0.694

0.000

-0.980

14.526

3.876

0.683

0.000

-0.989

14.592

3.880

0.680

0.000

-0.991

14.603

3.880

0.680

0.000

-1.000

14.672

3.885

0.677

0.000

-1.000

25.540

3.677

0.546

0.000

-0.996

27.500

3.500

0.531

Selecte
d

* The values of the independent parameters are coded according to the experimental
design
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Figure 23: Overlay plot showing the design space established using graphical
optimization for minimum residual crystallinity, minimum degradation and
maximum drug loading.
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4.8.7. Validation of Experimental Design
The design space was validated by preparing six confirmatory formulations within
the experimental domain. The linear correlation plots and the residual plots of all the
validation batches are shown in Figure 24. The values of bias were found to be 0.018 and
-0.61 for residual crystallinity and drug degradation, respectively (Table 10). Low values
of bias close to zero (‘0’) indicate that the model was unbiased. The prediction error was
found to be 5.72 and 9.94 for residual crystallinity and drug degradation, respectively.
Low values of bias and the prediction error indicate the high degree of predictability of
the experimental design.
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Table 10: The values of bias and percent error calculated from the validation batches

Residual crystallinity (%)
Degradation (%)
Drug Heating
Temp.
loading rate
( °C)
(%) (°C/min)
Pred.
Obs. Residual Pred.
Obs.
Residual
25

5

180

11.08 12.1±1.4

0.9815

7.98

8.86±0.28

16.1

25

10

200

4.80

5.4±0.69

0.6291

9.37

9.83±0.97

12.81

20

1

140

7.16

7.9±0.58

0.7333

9.09

10.53±0.78

-4.76

20

5

200

3.84

4.6±0.41

0.7885

9.77

10.46±1.48 -18.64

40

3

140

27.96 25.5±3.9 -2.3992

4.83

5.66±1.06

-15.04

40

10

180

27.48 26.9±2.31 -0.6208

8.78

9.73±1.93

5.83

Bias

0.018

-0.61

Percent Error

5.72

9.94
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Figure 24: Linear and residual plots between the observed and the predicted values of
residual crystallinity (a & b) and drug degradation (c & d), respectively.
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4.8.8. Hot Melt Extrusion and Vacuum Compression Molding Samples
Based on the design space obtained from the DSC experiments, 20% w/w MFAEPO dispersions were prepared using HME and VCM. The drug loading and final
heating temperature can be correlated directly with the HME process parameters.
However, the heating rate in DSC cannot be correlated to the screw speed in HME.
Therefore, three different samples were prepared at three different screw speeds (i.e., 50
rpm, 100 rpm and 150 rpm) to see the effect of screw speed on residual crystallinity and
% degradation. The HME filaments prepared at a screw speed of 100 rpm and 150 rpm
along with the VCM sample prepared at 150 °C are shown in Figure 25. The drugpolymer dispersions processed in HME at a screw speed of 50 rpm had high torque and
did not get extruded. The HME filaments obtained at a screw speed of 100 rpm and 150
rpm looked clear without any visible signs of MFA crystals. However, the filaments
obtained at a screw speed of 100 rpm did show slight discoloration. This could be due to
the degradation of drug or the polymer. The MFA-EPO dispersions processed in VCM at
150 °C for 3 minutes resulted in a clear dispersion with no evidence of phase separation.
To further confirm that the MFA-EPO dispersions prepared using HME and VCM
formed a homogeneous dispersion, DSC analysis was done, and the results are shown in
Figure 26. In all the three samples, no endothermic peak of the drug was observed
indicating that the MFA converted into amorphous form. Also, a single Tg was observed
at around 50 °C which shows that MFA was molecularly dispersed in EPO and there was
no phase separation. However, the HPLC analysis of the samples showed that 5% of
MFA was degraded in the VCM samples. In the case of HME samples, no degradation
was observed in filaments processed at 150 rpm as compared to 7.51% drug degradation
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in samples processed at 100 rpm (Table 11). This marked increase in MFA degradation at
100 rpm can be attributed to an increase in the residence time as compared to the samples
processed at 150 rpm. This shows the significance of the screw speed as an important
process parameter in HME. Also, it should be noted that the samples processed in HME
are subjected to both thermal and mechanical energy as compared to the samples
processed in DSC where only thermal energy is provided. This is the reason why no
residual crystallinity was observed in the HME filaments as compared to the samples
prepared in DSC. To further confirm that there is no residual crystallinity in the HME and
VCM samples, X-ray diffraction analysis was performed, and the results are shown in
Figure 27. The X-ray diffractogram of pure MFA revealed characteristic crystalline peaks
at 21.3° and 26.3° along with some crystalline peaks of lower intensity at 13.4°, 14.9°,
15.5°. These results suggest that pure MFA obtained from the vendor was a mixture of
form I and form II (59, 77). The X-ray diffractograms of drug-polymer dispersions
prepared using HME and VCM showed amorphous halo with no characteristic peak of
MFA. The results of XRD were in accordance to the DSC results and confirmed that
crystalline MFA had completely converted into amorphous form (78,79).
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Figure 25: MFA-EPO (20% w/w) ASDs prepared using hot melt extrusion at a screw
speed of 150 rpm and 100 rpm and vacuum compression molding (VCM)
prepared at 150 °C. The drug-polymer blends processed in HME at a screw
speed of 50 rpm had high torque and were unable to form filaments.
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Figure 26: DSC thermograms of 20% w/w drug loaded MFA-EPO dispersions prepared
using HME and VCM. A single glass transition temperature was observed in
all the samples at around 50 °C indicating that MFA and EPO formed a
monophasic system.
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Figure 27: Powder X-ray diffraction scans of pure mefenamic acid, vacuum compression
molding (VCM) sample, and hot-melt extrusion (HME) filaments processed
at screw speeds of 100 rpm and 150 rpm
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Table 11: Residual crystallinity and drug degradation of VCM and HME samples

Sample

Residual Crystallinity (%)

Degradation (%)

VCM

NA

5.0

HME – 100 rpm

NA

7.51

HME – 150 rpm

NA

NA

* NA indicate that no residual crystallinity/ drug degradation was observed in the
samples studied
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4.9. Effect of Temperature and Relative Humidity on Recrystalization
4.9.1. Determination of Recrystallization using DSC
The samples prepared using the heat molding method were analyzed using DSC
(DSC 6000, Perkin Elmer, USA) to ensure that crystalline MFA was completely
converted into an amorphous form. There was no endothermic peak observed in the DSC
scans indicating that the MFA crystals were completely converted into amorphous form
after the heat molding process. The samples were then stored at various temperature and
relative humidity conditions and the DSC scans were performed at various time points.
The DSC scans of 40% w/w drug loaded MFA-EPO solid dispersions at 40 °C and 75%
RH are shown in Figure 28. It was observed that the value of heat of fusion increased
with time indicating recrystallization. Figure 29 shows the rod shaped crystals of MFA
observed under a microscope. This indicates that recrystallization of MFA takes place in
a rod shaped with a dimensionality value, n=2. This helps to determine the
recrystallization rate constant, k, using the non-linear regression analysis.
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Figure 28: DSC thermograms showing the recrystallization of MFA over the period of
time evident from the increase in the heat of fusion (ΔH) values.
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Figure 29: Rod shaped crystals of MFA recrystallized from acetone. The magnified
image shows the perfect rod-shaped crystal of MFA under a microscope
(10X).
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4.9.2. Effect of Temperature on Recrystallization of MFA in EPO Matrix
The heat of fusion values (ΔHf) of MFA observed at various time points at
various temperatures and a constant relative humidity of 75% RH are shown in Table 12.
The plots between the relative crystallinity and time at 75% RH and various temperatures
are shown in Figure 30. At all the studied temperature ranges, it was observed that the
relative crystallinity increased rapidly and then became constant. Earlier publications
have reported a characteristic ‘S’ shaped curve for recrystallization of drugs in which the
recrystallization rate was low initially, due to nucleation, then rapid recrystallization due
to an increase in the nucleation sites and crystal growth followed by a flat phase that
corresponds to the decrease in the nucleation sites. However, in the present study, initial
nucleation sites were not observed. This could be due to the non-glass forming ability of
MFA which undergoes recrystallization when the samples are cooled. This resulted in the
formation of nucleation sites before the set experimental timelines (8 hr). However, rapid
recrystallization was observed at a later stage due to an increase in the nucleation sites.
The values of recrystallization rate, k, and the dimensionality constant, n, determined at
75% RH and various temperatures are given in Table 13. A plot of recrystallization rate
constant, k and temperature is shown in Figure 31. When n>0, the value of k at 25 °C, 40
°C and 60 °C was observed as 3.58×10-3 hr-n, 3.59×10-3 hr-n and 6.47×10-3 hr-n,
respectively. However, at 70° and 80 °C, the values increased to 21.05×10-3 hr-n and
44.04×10-3 hr-n, respectively. This exponential increase in the value of k can again be
attributed to an increase in the molecular mobility above the glass transition temperature,
Tg. When non-linear regression analysis was performed at n=2, the value of k at 25 °C, 40
°C, 60 °C, 70 °C and 80 °C was observed as 0.22×10-3 hr-n, 0.18×10-3 hr-n, 0.71×10-3 hr-n,
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2.50×10-3 hr-n and 7.25×103 hr-n, respectively. By comparing the values of k from both the
analysis, it can be inferred that the rate of recrystallization is low at lower temperature
and increases exponentially above the Tg of the drug-polymer dispersions. Using nonlinear regression analysis, higher values of recrystallization rate constant, k, were
predicted using the dimensionality constant, n, as >0 as compared to the values obtained
when n was fixed as 2. This was due to the flip-flop effect observed during non-linear
regression analysis (80). The average value of n predicted when n>0 was found to be 1.44
which is close to 2. This indicates that MFA recrystallizes as rod shaped crystals inside
the MFA polymeric matrix.
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Table 12: Values of heat of fusion of MFA recrystallized from the samples at various
temperatures and 75% RH.

Time
(hr)
8
12
18
24
48
72
96
120
144
168
192
216
240
264
288

25 °C/ 75%
RH

Heat of Fusion (ΔHf) J/g
40 °C/ 75% 60 °C/ 75% 70 °C/ 75%
RH
RH
RH

80 °C/ 75%
RH

6.8 ± 0.58
7.1 ± 0.70
9.95 ± 0.88
13.40 ± 1.77
14.58 ± 1.04
17.04 ± 0.86
17.81 ± 1.97
21.90 ± 1.25
23.32 ± 1.06
24.01 ± 1.54
23.94 ± 1.54
24.53 ± 1.34
24.72 ± 1.47

6.57 ± 0.56
7.49 ± 0.37
7.76 ± 0.30
8.95 ± 0.54
10.73 ± 0.85
13.92 ± 0.86
17.98 ± 1.46
20.95 ± 1.43
21.13 ± 0.79
21.98 ± 0.13
25.68 ± 1.16
26.28 ± 0.94
26.56 ± 1.02
26.86 ± 1.16

16.40 ± 1.77
22.43 ± 0.52
25.16 ± 2.19
36.23 ± 9.12
35.28 ± 6.44
40.05 ± 4.46
40.60 ± 5.99
40.65 ± 2.54
40.83 ± 2.66
41.22 ± 2.45
41.70 ± 2.06
42.15 ± 3.52
42.17 ± 3.25
41.45 ± 2.42
42.07 ± 2.25

9.85 ± 0.45
11.09 ± 2.90
12.26 ± 3.45
16.46 ± 1.17
24.67 ± 2.88
31.33 ± 1.09
39.60 ± 1.29
40.20 ± 2.58
43.24 ± 0.90
44.74 ± 0.90
45.96 ± 5.13
45.59 ± 2.57
46.10 ± 3.98
45.98 ± 2.96
46.73 ± 3.88

14.69 ± 1.85
15.18 ± 2.40
24.49 ± 3.39
30.73 ± 1.90
38.50 ± 2.68
44.75 ± 2.60
46.83 ± 1.20
48.25 ± 2.68
48.31 ± 3.79
50.94 ± 4.31
51.16 ± 4.26
51.01 ± 2.70
52.09 ± 2.08
51.83 ± 1.84
52.96 ± 2.36
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Figure 30: Relative crystallinity, α(t) as a function of time for 40% w/w drug loaded
MFA-EPO dispersions stored at various temperatures and 75% RH.
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Table 13: The values of recrystallization rate constant, k and dimensionality constant, n
of MFA at various temperatures and 75% RH.

n>0

Stability
conditions

k × 103 (hr-n)

n=2

n

R2

k × 103 (hr-n)

R2

25 °C / 75% RH

0.54 ± 0.89

1.89 ± 0.35

0.9225

0.31 ± 0.08

0.9139

40 °C / 75% RH

3.75 ± 2.56

1.47 ± 0.19

0.9452

0.66 ± 0.10

0.9348

60 °C / 75% RH

8.70 ± 4.10

1.37 ± 0.14

0.9689

1.10 ± 0.20

0.9522

70 °C / 75% RH

23.99 ± 3.73

1.27 ± 0.04

0.9792

2.04 ± 0.45

0.9257

80 °C / 75% RH

31.64 ± 6.97

1.43 ± 0.08

0.9738

7.65 ± 0.76

0.9268

The data are presented as mean±SE (standard error of fit)
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Figure 31: Relationship between the recrystallization rate constant, k, and temperature at
a dimentionality value of n = 2 and n > 0.
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4.9.3. Arrhenius Plot of Recrystallization as a Function of Temperature
The Arrhenius plot was constructed by ploting the values of log k vs 1/T that
revealed that the crystallization rate increased exponentially with temperature, T, within
the temperature range studied implying that the Arrhenius equation expresses the
temperature dependence of recrystallization rate (Fig. 32). The recrystallization activation
energy, ΔEa, was determined from the slope of the linear regression of ln k and 1/T. The
activation energy allows the prediction of recrystallization kinetics at temperature outside
the experimental range. The value of activation coefficient, ΔEa, was found to be 63,024
J/mol (15.06 Kcal/mol) when n>0 and 44,828 J/mol (10.74 Kcal/mol) when n=2. This
value of activation energy, ΔEa, can be used to determine the recrystallization rate at
various temperatures.
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Figure 32: Arrhenius plot of crystallization rate constant, k, as a function of inverse of
temperature, 1/T for 40% w/w drug loaded MFA-EPO dispersions.
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4.9.4. Effect of Relative Humidity on Recrystallization of MFA in EPO Matrix
The values of heat of fusion, ΔHf, of MFA observed at various time points at
various relative humidity conditions and a constant temperature of 60 °C are shown in
Table 14. The plots between the relative crystallinity and time at 60 °C and various
relative humidity conditions are shown in Figure 33. At the relative humidity range
studied, it was observed that the relative crystallinity increased rapidly and then became
constant. The experimental values correlated well with the kinetic model at all the
relative humidity conditions except at 11% RH where the kinetic model overpredicted the
relative crystallinity (black squares as outliers in Fig. 33). Similar to the effect of
temperature, no nucleation sites were observed in the samples stored at various relative
humidity conditions. The values of recrystallization rate, k, and the dimensionality
constant, n, determined at 60 °C and various relative humidity conditions are given in
Table 15. A plot of recrystallization rate constant, k, and temperature is shown in Fig. 34.
When non-linear regression analysis was performed at n>0, the values of k at 11% RH,
22% RH, 32% RH, 60% RH and 75% RH were 2.02×10-3 hr-n, 4.98×10-3 hr-n, 5.03×10-3
hr-n, 5.58×10-3 hr-n and 6.47×10-3 hr-n, respectively. When non-linear regression analysis
was performed at n=2, the values of k at 25 °C, 40 °C, 60 °C, 70 °C and 80 °C were
0.19×10-3 hr-n, 0.53×10-3 hr-n, 0.74×10-3 hr-n, 0.75×10-3 hr-n and 0.71×10-3 hr-n,
respectively. Upon comparing the values of k by both the analyses, it can be inferred that
the rate of recrystallization was low at 11% RH and increased at 32%RH, 60% RH and
75% RH conditions. As described earlier, the experimental data at 11% RH did not fit
well with the kinetic model used in this study.
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Table 14: Values of heat of fusion of MFA recrystallized from the samples at 60 °C
temperature and various relative humidities
Time 60 °C/11%
(hr)
RH
8
6.7 ± 0.5
12
7.7 ± 0.5
18
10.1 ± 1.3
24
10.1 ± 0.8
48
15.1 ± 2.7
72
20.6 ± 2.4
96
22.2 ± 0.8
29.3 ± 1.4
120
144
30.7 ± 0.7
168
37.4 ± 0.5
192
42.2 ± 2.8
216
43.7 ± 0.9
240
44.1 ± 4.5
264
44.4 ± 3.3
288
43.2 ± 4.2

60 °C/22%
RH
11.9 ± 2.0
11.6 ± 1.2
12.3 ± 1.6
14.7 ± 1.3
28.6 ± 3.6
35.6 ± 4.7
36.6 ± 2.9
38.1 ± 4.2
38.4 ± 2.7
40.9 ± 3.9
43.7 ± 4.0
43.7 ± 3.1
45.3 ± 3.9
44.8 ± 4.8
45.5 ± 3.2

60 °C/32%
RH
8.1 ± 0.8
7.5 ± 0.2
8.0 ± 1.1
18.0 ± 1.4
26.3 ± 2.6
29.7 ± 0.1
34.7 ± 2.9
37.4 ± 1.4
39.2 ± 2.2
40.9 ± 2.4
41.5 ± 3.6
42.3 ± 2.7
42.9 ± 1.8
43.2 ± 4.2
43.9 ± 3.9

60 °C/60% RH

60 °C/75% RH

9.13 ± 1.64
10.00 ± 0.34
11.03 ± 1.30
15.09 ± 1.66
22.81 ± 0.99
28.96 ± 0.84
36.51 ± 1.99
37.15 ± 0.83
40.00 ± 1.09
41.40 ± 4.41
42.12 ± 1.55
42.02 ± 2.32
42.32 ± 1.25
42.30 ± 1.40
42.94 ± 2.04

9.85 ± 0.45
11.09 ± 2.90
12.26 ± 3.45
16.46 ± 1.17
24.67 ± 2.88
31.33 ± 1.09
39.60 ± 1.29
40.20 ± 2.58
43.24 ± 0.90
44.74 ± 0.90
45.96 ± 5.13
45.59 ± 2.57
46.10 ± 3.98
45.98 ± 2.96
46.73 ± 3.88

*All the experiments were performed in triplicate and the values are represented as mean
± SD (n=3)

129

Figure 33: Relative crystallinity, α(t), as a function of time for 40% w/w MFA-EPO
dispersions at 60 °C temperature and various relative humidities.
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Table 15: Values of recrystallization rate constant, k, and dimensionality constant, n, of
MFA at 60 °C temperature and various relative humidities
Stability
conditions

n>0
k × 103 (hr-n)

n

11% RH/ 60 °C

5.06 ± 4.87

22% RH/ 60 °C

n=2
R2

k × 103 (hr-n)

R2

1.29 ± 0.20

0.8588

0.16 ± 0.03

0.8322

5.12 ± 2.89

1.49 ± 0.13

0.9045

0.55 ± 0.08

0.8751

32% RH/ 60 °C

5.77 ± 1.94

1.51 ± 0.07

0.9286

0.60 ± 0.11

0.8732

60% RH/ 60 °C

6.41 ± 3.45

1.43 ± 0.16

0.9694

0.93 ± 0.17

0.9130

75% RH/ 60 °C

8.70 ± 4.10

1.37 ± 0.14

0.9690

1.10 ± 0.20

0.9522

The data are presented as mean±SE (standard error of fit)

131

Figure 34: Plot showing relationship between the recrystallization rate constant, k, and
relative humidity at a dimentionality value of n = 2 and n > 0 at 60 °C.
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4.9.5. Effect of Relative Humidity on Recrystallization of MFA in EPO Matrix at
Room Temperature
To understand the effect of relative humidity on recrystallization of MFA at room
temperature, 25° C, the MFA-EPO (40% w/w) dispersions were further stored at 32±5%
RH and 75±5% RH and a temperature of 25±2 °C. The amount of MFA recrystallized
from the drug-polymer dispersions at different time points was determined using DSC
and the recrystallization rate constant was estimated using modified Avarami equation.
The heat of fusion (ΔHf) values of MFA recrystallized at different relative humidities of
11%, 32% and 75% and temperature of 25 °C were given in Table 16. By comparing the
heat of fusion values at room temperature and at 60 °C, it can be observed that after 288
hrs, the values of ΔHf at 25 °C are significantly lower than that observed at 60 °C. This
shows that recrystallization of MFA at room temperature is slower than that observed at
60 °C, which is close to the glass transition temperature of the drug-polymer system. The
rate of recrystallization was calculated using non-linear regression analysis. The
relationship between the reltive crystallinity and time is show in Figure 35. It can be
observed that the relative crystallinity, α(t), was observed to be increasing linearly rather
than exhibiting the characteristic ‘S’ shaped curve that was observed at higher
temperatures. This show that the rate of recrystallization is slow and the drug-polymer
system did not undergo nucleation, followed by crystal growth. In such cases, the data
used to estimate the recrystallization rate will not fit the modified Avarami model. This is
evident from the values of rate of recrystallization, k observed at various relative humidty
and at room temperature as shown in Table 17 and Figure 36. The overestimated values
at 11% and 32% RH is due to incomplete recrystallization of MFA in EPO matrix.
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Table 16: Values of heat of fusion of MFA recrystallized from the samples stored at 25
°C temperature and various relative humidities

Time (hr)

11% RH/ 25 °C

32% RH/ 25 °C

75% RH/ 25 °C

8

7.47 ± 1.04

11.00 ± 2.58

NA

12

8.10 ± 0.83

13.85 ± 2.60

NA

18

9.86 ± 1.57

13.57 ± 4.18

6.83 ± 0.58

24

10.51 ± 0.40

16.34 ± 4.05

7.09 ± 0.70

48

11.67 ± 2.95

17.03 ± 3.69

9.95 ± 0.88

72

16.80 ± 2.58

16.97 ± 4.70

13.40 ± 1.77

96

17.54 ± 2.37

17.60 ± 4.71

14.58 ± 1.04

120

15.87 ± 1.43

19.51 ± 2.79

17.04 ± 0.86

144

17.94 ± 2.69

17.96 ± 2.05

17.81 ± 1.97

168

15.31 ± 1.65

20.26 ± 2.11

21.90 ± 1.25

192

15.45 ± 2.19

19.65 ± 0.94

23.32 ± 1.06

216

16.14 ± 1.89

21.19 ± 1.51

24.01 ± 1.54

240

17.08 ± 1.25

20.66 ± 1.35

23.94 ± 1.59

264

16.67 ± 1.11

20.19 ± 1.27

24.53 ± 1.34

288

18.22 ± 0.71

20.69 ± 1.41

24.72 ± 1.47

All the experiments were performed in triplicate and the values are represented as mean ±
SD (n=3)
NA - No melting endotherm was observed
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Figure 35: Plot of relative crystallinity, α(t), as a function of time for 40% w/w drug
loaded MFA-EPO dispersions at 25 °C temperature and various relative
humidity conditions
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Table 17: The values of recrystallization rate constant, k, and dimensionality constant, n,
of MFA at 25 °C temperature and various relative humidity conditions
Stability
conditions

n>0
k × 103 (hr-n)

n

n=2
R2

k × 103 (hr-n)

R2

11% RH/ 25 °C

90.94 ± 21.4

0.86 ± 0.07

0.9652

0.16 ± 0.03

0.7301

32% RH/ 25 °C

94.69 ± 65.14

1.17 ± 0.23

0.7584

0.60 ± 0.11

0.6685

75% RH/ 25 °C

8.70 ± 4.10

1.37 ± 0.14

0.9690

1.10 ± 0.20

0.9522

The data are presented as represent mean ± SE (standard error of fit)
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Figure 36: Relationship between the recrystallization rate constant, k and relative
humidity at a dimentionality value of n = 2 and n > 0 at a temperature of 25
°C.
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4.9.6. Effect of Drug Loading on Recrystallization at 40 °C and 75% RH
In earlier studies, the intermolecular interaction between the carboxylic acid of
MFA and the aminoalkyl group of EPO was reported. Based on this, it is speculated that
a stable system of MFA and EPO occurs within a stochiometric ratio; and when the drug
loading is more than the stochiometric ratio, changes in the temperature and relative
humidity cause phase separation. To test this hypothesis, the absolute amount of MFA
recrystallized from the samples at various RH conditions was calculated. It was found
that ~50% of the drug loading (40% w/w) recrystallized out irrespective of the RH
conditions. That means, only 20% of MFA remained kinetically stable in the samples
even at high relative humidity conditions. This value is close to the miscibility value of
MFA in EPO predicted using thermodynamic phase diagrams. To further test this
hypothesis, 30% MFA-EPO and 50% MFA-EPO samples were prepared and stored at 40
°C and 75% RH. The enthalpy values were determined, and the extent of recrystallization
were calculated for 45 day (Fig. 37). The % drug miscible in the polymeric matrix at
various drug loading was calculated and it was observed that irrespective of the drug
loading, around 25% of MFA was miscible in EPO matrix even when subjected to
extreme climatic conditions of 40 °C and 75% RH (Fig. 38).
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Figure 37: Plot demonstrating relationship between the % drug recrystallization and time
at various drug loading of 30%, 40% and 50% w/w of MFA and EPO.
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Figure 38: Effect of drug loading on drug miscibility. The red circles represent
amorphous drug and the polygons represent the recrystallized drug.
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5. Summary and Conclusions
The determination of ideal drug-loading and processing temperature for hot-melt
extrusion to develop amorphous solid dispersions (ASDs) is challenging and often
requires extensive experimentation. While theoretical concepts of solubility parameters
are reportedly used for initial screening of polymeric excipients for such formulations,
their applicability is limited only to some drug-polymer combinations. In the present
investigations, therefore, thermodynamic aspects of mixing a non-glass forming drug,
mefenamic acid (MFA), in four chemically distinct polymeric excipients with close
values of Hansen and Hildebrand solubility parameters were studied. The rank order
miscibility of MFA in the four polymeric carriers studied was estimated based on the
difference in the values of solubility parameters, Δδ, between the drug and the polymer.
Based on the difference in the values of the solubility parameters, Δδ, it was deduced that
MFA will be miscible in all the four polymers studied. However, the values of
interaction parameters, χ, calculated from the melting point depression data suggested
that while MFA would have good miscibility in EPO, SLP, and VA64, it would have
poor miscibility in F68 despite a difference in the value of solubility parameter, ∆δ, less
than 7 MPa0.5; a value of ∆δ < 7 MPa0.5 is considered to suggest good drug-polymer
miscibility. This suggests that the values of solubility parameters can lead to an
overestimation of the degree of miscibility of the drugs and the polymeric excipients, and
a difference in the value of solubility parameter, ∆δ, less than 7 MPa0.5 does not
necessarily always indicate good drug-polymer miscibility. Further, a systematic
approach for the construction of thermodynamic phase diagrams and Gibbs free energy
plots using the melting point depression data was also conducted. The Berghmans point
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in the thermodynamic phase diagrams of MFA with various polymeric carriers studied
showed that the predicted miscibility of MFA in both EPO and SLP was ~13% w/w, and
in VA64 and F68 it was less than 5% w/w. The upper critical solution temperature
(UCST) of drug-polymer mixtures predicted from the Gibbs free energy plots showed
that MFA will be miscible in EPO and SLP in all proportions at a processing temperature
above 140 °C; in the case of VA64 and F68, the upper critical solution temperature
(UCST) was above 200 °C. The observations from the initial investigations thus lead to
the conclusion that theoretical approaches, such as estimation of Hildebrand and Hansen
solubility parameters and construction of the Bagley plot, should be used with caution in
the assessment of drug-polymer miscibility, and the results from the thermodynamic
phase diagrams and the Gibbs free energy plots will provide a better assessment tool for
the selection of the ideal drug-loading and processing temperature for hot-melt extrusion
process thereby reducing the total time and material required for the product and the
process development.
To determine the ideal processing conditions required for HME and to understand
the relationship between the processing parameters, i.e. drug loading, residence time and
the processing temperature, a material sparing DSC method was developed. In this work,
the residual crystallinity and degradation of MFA in EPO polymeric matrix as a function
of drug loading, DSC heating rate and DSC heating temperature was examined using
Box-Behnken experimental design. The results showed that the studied process
parameters had significant effect on the residual crystallinity and drug degradation. A
quadratic relationship was obtained between the studied independent parameters and the
dependent parameters. In general, it was found that an increase in drug load resulted in an
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increase in residual crystallinity, while an increase in temperature resulted in decrease in
residual crystallinity. An increase in the temperature and decrease in the heating rate
increased the drug degradation. Numerical and graphical optimization were used to
predict the design space of the processing conditions which result in minimum residual
crystallinity and minimum drug degradation. It was found that when a drug load of 20%
w/w was processed at a heating rate of 5.5 °C/min and temperature of 146 °C, the
resulting product had residual crystallinity of 13.6% and drug degradation of 3.8%. Based
on the design space obtained from the experimental design, 20% w/w drug loaded MFAEPO dispersions were prepared using HME and VCM. The drug-polymer dispersions
obtained using both HME and VCM did not show any signs of residual crystallinity of
MFA. However, degradation of MFA was observed in VCM sample and the HME
filaments processed at 100 rpm, but not at 150 rpm. This reiterates the significance of
adjusting the screw speed during HME process.
Once the optimized ASDs were obtained, their physical stability was determined by
storing at accelerated conditions of 40 °C and 75% RH for three months. In practice, if
recrystallization of the amorphous drug is observed after three months, the whole
optimization process is performed again, resulting in loss of valuable time. Therefore, in
the present investigation, a modified Avarami model was used to determine the physical
stability of ASDs within an experimentally feasible time-frame. The rate of
recrystallization calculated using the modified Avarami equation showed that
temperature had a significant effect on the rate of recrystallization as compared to the
relative humidity. The absolute crystallinity of MFA observed at three different drug
loadings (30%, 40% and 50% w/w) was found to be similar after storing at 40 °C/75%
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RH. This showed that the amount of drug that was miscible in the polymeric carrier
remained in the amorphous form even after subjecting to accelerated stability conditions.
A work flow chart illustrating the formulation development process of ASDs using
HME is shown in Figure 39. In summary, selection of the ideal polymer and the
processing temperature can be first determined using thermodynamic phase diagrams and
Gibbs free energy plots. Once the ideal polymer and the miscibility of the drug in the
polymer is determind, the HME process can first be designed using a DSC to determine
the ideal drug-loading and processing temperature (i.e., the design space). Once the
design space is identified, the optimization of screw configuration and screw speed can
be performed by either in silico simulations and/or by conducting a few HME
experiments. Finally, the physical stability of the optimized ASDs can be determined at
various temperatures and relative humidity conditions using the modified Avarami
equation, thereby predict the shelf life of the ASDs. This approach significantly reduces
the total number of experiments required to setup the HME process, thereby making the
whole product development cost efficient.
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Figure 39: Flow chart summarizing the material-sparing approach for the formulation
development of ASDs using HME
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